Publications

  1. Drosos AA, Brennan PJ, Elisaf M, Stefanou SG, Papadimitriou CS, Moutsopoulos HM. Specific antigen and antibody to Mycobacterium lepra in the cryoprecipitate of a patient with Lucio phenomenon. Rheumatol Int 6: 93 - 94, 1986
  2. Siamopoulos KC, Mavridis AK, Elisaf M, Drosos AA, Moutsopoulos HM. Kidney involvement in primary Sjogren's syndrome. Scand J Rheumatology 61: 156 - 160, 1986
  3. Elisaf M, Litou H, Siamopoulos KC. Survival after severe iatrogenic hypernatremia. Am J Kidney Dis 14: 230 - 231, 1989
  4. Moutsopoulos HM, Cledes J, Skopouli FN, Elisaf M, Youinou P. Nephrocalcinosis in Sjogren's syndrome. A late sequela of renal tubular acidosis. J Intern  Med 230: 187 - 191, 1991
  5. Elisaf M, Tsianos E, Mavridis A, Dardamanis M, Pappas M, Siamopoulos KC. Antibodies against hepatitis C virus (anti - HCV) in hemodialysis patients: association with hepatitis B serologic markers. Nephrol Dial Transplant 6 : 476 - 479, 1991
  6. Elisaf M, Dardamanis M, Pappas M, Sferopoulos G, Siamopoulos KC. Treatment of nephrotic hyperlipidemia with lovastatin. Clin  Nephrol 36 : 50 - 52, 1991
  7. Elisaf M, Stefanaki - Nikou S, Drosos AA, Moutsopoulos HM. Atrophie blanche. Ann Med Interne   142 (6) :  415 - 418,  1991
  8. Drosos AA, Pennec YL, Elisaf M, Lamour A, Acritidis NC, Jouquan S, Moutsopoulos HM, Youinou P. Sjogren's syndrome in patients with the CREST variant of progressive systemic sclerosis.  J Rheumatol  18 : 1685 - 1688,  1991
  9. Siamopoulos KC, Elisaf M, Drosos AA, Mavridis AA, Moutsopoulos HM. Renal tubular acidosis in primary Sjogren's syndrome. Clin Rheumatol 11: 226 - 230, 1992
  10. Siamopoulos KC, Elisaf M, Pappas M. Severe asymptomatic hyperglycemia in a non - diabetic CAPD patient. Perit Dial Int 12 : 72 - 73, 1992
  11. Elisaf M, Stefanaki - Nikou S, Voulgarelis M, Masalas C, Tsianos EV. Apridine - induced hepatic granulomas. J Hepatol 14: 276 - 279, 1992
  12. Siamopoulos KC, Elisaf M, Dardamanis M, Sferopoulos G, Pappas M. Effects of isradipine on hypertension and renal hemodynamics. J Cardiovasc Pharmacol 19 (3): S87-S89, 1992
  13. Elisaf M, Kaftatzis K, Siamopoulos KC. Hemorrhagic fever with renal syndrome: diagnostic value of the radiologic manifestations. Cyprus Med J 10: 10 - 14, 1992
  14. Elisaf M, Boulgarelis M, Siamopoulos KC. Idiopathic oedema in a male.            Eur J Intern Med 1(6): 376 - 377, 1992
  15. Siamopoulos KC, Elisaf M, Antoniadis A, Moutsopoulos HM. Hemorrhagic fever with renal syndrome in an Endemic Area of Greece. Am J Nephrol 12: 170 - 173, 1992
  16. Elisaf M, Dardamanis M, Pappas M, Sferopoulos G, Siamopoulos KC. Long term treatment of nephrotic hyperlipidemia with lovastatin. Cardiovasc Risk Factors 2: 387 - 392, 1992
  17. Elisaf M, Dardamanis M, Papagalanis ND, Siamopoulos KC. Lipid abnormalities in chronic uremic patients. Response to treatment with gemfibrozil. Scand J Nephrol Urol 27: 101 - 108, 1993
  18. Papagalanis N, Kourti A, Tolis A, Skopelitis P, Karabatsos A, Kostogianni G, Genadiou M, Elisaf M, Mountokalakis T. Effect of intravenous calcium infusion on indices of activity of the parathyroid glands and on urinary calcium and sodium excretion in normotensive and hypertensive subjects. Am J Hypertens 6: 59 - 65, 1993
    1. Mέχρι του σημείου αυτού είχα υποβάλει βιογραφικό σημείωμα για υποψηφιότητα σαν Eπίκουρος Kαθηγητής Παθολογίας
  19. Elisaf M, Stefanaki S, Repanti M, Korakis H, Tsianos E, Siamopoulos KC. Liver involvement in haemorrhagic fever with renal syndrome. J Clin Gastroenterol 17(1): 33 - 37, 1993
  20. Elisaf M, Papanikolaou N, Letzaris G, Dimoliatis J, Siamopoulos KC. Atherosclerotic risk factors in female students of Northwestern Greece. J Hum Hypertens 7: 533 - 537, 1993
  21. Elisaf M, Papagalanis ND, Siamopoulos KC. The importance of serum sodium in the symptomatology of hyperglycemic - induced hypertonicity. J Nephrol 6: 202 - 205, 1993
  22. Tsianos EV, Dalekos GN, Elisaf M, Zervou E, Siamopoulos KC. High frequency of antibodies to Hantaan virus and Hepatitis C virus in hemodialysis patients. Coincidence or cross reaction. J Intern Med 234: 607 - 610, 1993
  23. Elisaf M, Korakis H, Siamopoulos KC. Chronic renal dysfunction in hemorrhagic fever with renal syndrome patients. Renal Failure 15(5): 623 - 627, 1993
  24. Elisaf M, Antoniadis A, Siamopoulos KC. Mild human infections of HFRS in Northwestern Greece. J Virol 1(2): 28 - 30, 1993
  25. Elisaf M, Theodorou J, Pappas H, Siamopoulos KC. Acid - base and electrolyte abnormalities in febrile patients with bacteremia. Eur J Med 2: 404 - 407, 1993
  26. Pavlidis N, Elisaf M, Bai M, Tolis C, Papademitriou C. Primary lymphoma of the pericardium. Report on a "cured" case. Med Pediatr Oncol 22: 287 - 291, 1994
  27. Papagalanis N, Genadiou M, Karabatsos A, Fenekos K, Elisaf M, Kourti A, Zacharof A, Siamopoulos K, Mountokalakis T. Effect of an acute oral protein loading on microalbuminuria in uninephrectomized subjects in relation to the time since nephrectomy. Nephron 68: 169 - 179, 1994
  28. Siamopoulos KC, Elisaf M, Moutsopoulos HM. Hypokalemic paralysis as the presenting manifestation of primary Sjögren’s syndrome. Nephrol Dial Transplant 9: 1176 - 1178, 1994
  29. Tsianos EV, Dardamanis M, Vasakos S, Elisaf M, Siamopoulos KC. The value of a - amylase determination in patients with chronic renal failure. Intern J Pancreatol 15: 105 - 111, 1994
  30. Elisaf M, Bairaktari E, Tzallas G, Germanos N, Koulouridis E, Pappas M, Siamopoulos KC, Tsolas O. Lipid parameters including Lp(a) in hemodialysis patients. Renal Failure  16(4): 501 - 509, 1994
  31. Elisaf M, Merkouropoulos M, Tsianos EV, Siamopoulos KC. Acid - base and electrolyte abnormalities in alcoholic patients. Miner Electrolyte  Metab  20: 274 - 281, 1994
  32. Dalekos GN, Liapi GC, Dallas P, Stefanou D, Elisaf M. Stauffer's syndrome as first manifestation of renal cell carcinoma. A case report. Eur J Intern Med 5: 319 - 320, 1994
  33. Elisaf M, Siamopoulos KC. Pulmonary involvement in HFRS patients in Greece. Chest 107: 588 - 589, 1995
  34. Elisaf M, Siamopoulos KC. Fractional excretion of potassium in normal subjects and in patients with hypokalemia. Postgrad Med J 71: 211 - 212, 1995
  35. Dalekos GN, Zervou E, Karabini F, Elisaf M, Bourantas K, Siamopoulos KC. Prevalence of antibodies to human T - lymphotropic virus types I and II in volunteer blood donors and high risk groups in Northwestern Greece. Transfusion 35: 503 - 506, 1995
  36. Elisaf M, Bairaktari H, Tsolas O, Siamopoulos KC. Lp(a) levels in diabetic hemodialysis patients. J Nephrol 8: 198 - 201, 1995
  37. Elisaf M, Siamopoulos KC. Bacteremia - induced hypomagnesemia. Magnesium - Bulletin 17: 70 - 73, 1995
  38. Elisaf M, Theodorou J, Pappas C, Siamopoulos KC. Successful treatment of hyponatremia with converting enzyme inhibitors in patients with heart failure. Cardiology 86: 477 - 480, 1995
  39. Elisaf M, Papagalanis N, Siamopoulos KC. Pathogenetic mechanisms of alkalemia in acute renal failure patients. It J Mineral Electr Metabolism 9: 27 - 29, 1995
  40. Elisaf M, Katopodis K, Bouradas K, Siamopoulos KC. Hyperkalemic hyperchloremic metabolic acidosis in a patient with sickle cell β - thalassemia. Am J Hematol 50: 151 - 152, 1995
  41. Siamopoulos KC, Elisaf M, Bairaktari H, Pappas M, Sferopoulos G, Nikolakakis N. Lipid parameters including Lp(a) in patients undergoing continuous ambulatory peritoneal dialysis and hemodialysis. Perit Dial Int 15: 342 - 347, 1995
  42. Dardamanis MA, Elisaf MS, Vasakos SA, Tsianos EV, Siamopoulos KC. α - Amylase and isoamylases levels in renal transplant recipients compared to uremic patients. Renal Failure 17(6): 715 - 719, 1995
  43. Elisaf MS, Bairaktari HT, Tzallas CS, Germanos NK, Siamopoulos KC. Atherogenic lipid and lipoprotein parameters in hemodialysis patients. Dial Transplant 24(11): 642 - 660, 1995
  44. Fatouros M, Bourantas K, Bairaktari E, Elisaf M, Tsolas O, Cassioumis D. The role of the spleen in lipid metabolism in rats.  Br J Surg 82: 1675 - 1677, 1995
  45. Elisaf M, Merkouropoulos M, Tsianos EV, Siamopoulos KC. Pathogenetic mechanisms of hypomagnesemia in alcoholic patients. J Trace Elements Med Biol 9: 210 - 214, 1995
  46. Elisaf M, Mikhailidis D, Siamopoulos KC.  Dyslipidemia in patients with renal diseases. J Drug Dev Clin Pract 7: 331 - 348, 1996
  47. Elisaf M, Pappas H, Siamopoulos KC. Polyglandular autoimmune syndrome presenting as acute renal failure with severe hyperkalemia. Nephron 72: 497 - 498, 1996
  48. Elisaf M, Konstantinides A, Siamopoulos KC. Chronic hyponatremia due to reset osmostat in a patient with colon cancer. Am J Nephrol 16: 349 - 351, 1996
  49. Elisaf M, Bairaktari H, Siamopoulos KC. Lp(a) levels in Greek patients with heterozygous familial hypercholesterolemia. Intern J Cardiol 53: 314 - 316, 1996
  50. Elisaf M, Papanikolaou N, Letzaris G, Siamopoulos KC. Smoking habit in female students of Northwestern Greece: relation to other cardiovascular risk factors. J Royal Soc Health 116: 87 - 90, 1996
  51. Elisaf M, Katopodis K, Siamopoulos KC. Lp(a) concentration and serum albumin levels in hemodialysis patients. Nephrol Dial Transplant 11: 908, 1996
  52. Siamopoulos KC, Papanikolaou S, Elisaf M, Theodorou J, Pappas H, Papanikolaou N. Ambulatory blood pressure monitoring in normotensive pregnant women. J Hum Hypertens 10 (Suppl 3): S 51 - S 54, 1996
  53. Elisaf M, Pappas H, Kalaitzidis R, Theodorou J, Siamopoulos KC. Ambulatory blood pressure monitoring in hemodialysis patients. J Hum Hypertens 10 (Suppl 3): S43 - S47, 1996
  54. Tsatsoulis A, Pappas C, Elisaf M, Siamopoulos KC. Thyroxine - induced Addisonian crisis in a patient with unrecognised autoimmune polyglandular syndrome type II. Eur J Intern Med 7: 127 - 129, 1996
  55. Elisaf M, Siamopoulos KC. Survival after severe diabetic ketoacidosis. Eur J Intern Med 7: 107 - 108, 1996
  56. Elisaf M, Siamopoulos KC. Lp(a) concentration in patients with renal diseases. Am J Kidney Dis 28: 307, 1996
  57. Karabina S-AP, Elisaf M, Goudevenos J, Siamopoulos KC, Sideris D, Tselepis A. PAF - acetylhydrolase activity on Lp(a) before and after Cu2+ - induced oxidative modification in vitro. Atherosclerosis 125: 121 - 134, 1996
  58. Elisaf M, Milionis H, Siamopoulos KC. Agranulocytosis due to long - term vancomycin treatment. Eur J Intern Med 7: 132, 1996
  59. Elisaf MS, Bairaktari ET, Tzallas CS, Siamopoulos KC. The hypolipidemic effectiveness of antacids containing aluminum alone and in combination with small doses of pravastatin. J Drug Dev Clin Pract 8: 101 - 107, 1996
  60. Elisaf M, Bairaktari H, Germanos N, Pappas M, Koulouridis E, Papagalanis N, Siamopoulos KC. Long - term effects of low molecular weight heparin on lipid parameters in hemodialysis patients. Int J Angiol 15: 252 - 256, 1996
  61. Elisaf M, Bairaktari H, Tzallas Ch, Nicolaides C, Siamopoulos KC, Tsolas O, Pavlidis N. The beneficial effect of tamoxifen (TMX) on the serum lipoprotein A (Lp - a) levels: an additional anti - atherogenic property of TMX. Anticancer Res 16: 2725 - 2728, 1996
  62. Elisaf M, Milionis H, Siamopoulos KC. Chronic hyponatremia secondary to reset osmostat in a patient with advanced ovary cancer. J Exp Clin Cancer Res 15: 313 - 314, 1996
  63. Elisaf M, Siamopoulos KC. Are the increased Lp(a) levels in hemodialysis patients related to glucose intolerance and hemodialysis duration? Nephron 74: 623 - 624, 1996
  64. Elisaf M, Bairaktari H, Tzallas Ch, Milionis H, Siamopoulos KC. Increased Lp(a) levels in patients with proteinuria. Cardiovasc Risk Factors 6: 289 - 293, 1996
  65. Katopodis K, Elisaf M, Siamopoulos KC. Hypophosphatemia in a patient with Gitelman's syndrome. Nephrol Dial Transplant 11: 2090 - 2092, 1996
  66. Dalekos G, Elisaf M, Papagalanis N, Tzallas C, Siamopoulos KC. Elevated interleukin - 1β in the circulation of patients with essential hypertension. Eur J Clin Invest 26: 936 - 939, 1996
  67. Elisaf M, Tsatsoulis AA, Katopodis K, Siamopoulos KC. Acid - base and electrolyte disturbances in patients with diabetic ketoacidosis. Diab Res Clin Pract 34: 23 - 27, 1996
  68. Tselepis A, Elisaf M, Goudevenos J, Tselegaridis Th, Bairaktari E, Siamopoulos KC, Sideris D. Lipid profile in patients with microvascular angina. Eur J Clin Invest   26: 1150 - 1155, 1996
  69. Hatzioannidis VG, Elisaf M,  Hassiotis G, Salachas AJ, Goudevenos I, Sideris DA. The effects of exercise testing on haematological, biochemical and electrolyte parameters. Eur J Intern Med   7: 191 - 194, 1996
  70. Milionis H, Elisaf M. Transient global amnesia after bone marrow aspiration. Eur J Intern Med 7: 259, 1996
  71. Elisaf M, Siamopoulos KC. Serum anion gap: re-evaluation of normal values. Br J Clin Pract 50: 411, 1996
  72. Elisaf M, Siamopoulos KC. Mechanisms of hypokalemia in alcoholic patients. It J Miner Electrolyte Metab 10: 159 - 163, 1996
    1. Mέχρι του σημείου αυτού είχα υποβάλει βιογραφικό σημείωμα
    2. για υποψηφιότητα σαν Aναπληρωτής Kαθηγητής Παθολογίας
  73. Elisaf M, Siamopoulos KC.  Diagnosis and treatment of hyponatraemia in SIAD. Nephrol Dial Transplant 12: 1079, 1997
  74. Dalekos G, Elisaf M, Bairaktari E, Tsolas O, Siamopoulos KC. Increased serum levels of interleukin - 1β in the systemic circulation of patients with essential hypertension: An additional risk factor for atherogenesis in hypertensive patients? J Lab Clin Med 129: 300 - 308, 1997
  75. Elisaf M, Siamopoulos KC, Tselegarides T, Bairaktari E, Goudevenos J, Tselepis A, Tsolas O, Sideris D. Lipid abnormalities in Greek patients with coronary artery disease. Intern J Cardiol 59: 177 - 184, 1997
  76. Elisaf M, Germanos N, Bairaktari H, Pappas M, Koulouridis E, Siamopoulos KC. The effects of conventional vs low molecular weight heparin on lipid profile in hemodialysis patients. Am J Nephrol 17: 153 - 157, 1997
  77. Siamopoulos KC , Elisaf M. Is CAPD atherogenenic? (Editorial). Perit Dial Int 17: 227 - 231, 1997
  78. Elisaf M, Milionis H, Siamopoulos KC. Hypomagnesemic hypokalemia and hypocalcemia: Clinical and laboratory characteristics. Miner Electrolyte Metab 23: 105 - 112, 1997
  79. Elisaf M, Terrovitou Ch, Tomos P, Siamopoulos KC. Severe hyperkalaemia after cotrimoxazole administration in a patient with hyporeninaemic hypoaldosteronism. Nephrol Dial Transplant 12: 1254 - 1255, 1997
  80. Elisaf M, Milionis H, Siamopoulos KC. Electrolyte abnormalities in elderly patients admitted to a general medical ward. Geriatr Nephrol Urol 7: 73 - 79, 1997
  81. Elisaf M, Bairaktari E, Tzallas C, Siamopoulos KC. Lipoprotein (a) concentration in patients with various dyslipidemias. Ann Med 29: 305 - 309, 1997
  82. Karabina S-AP, Elisaf M, Bairaktari E, Tzallas C, Siamopoulos KC, Tselepis AD. Increased activity of platelet - activating factor acetylhydrolase in low - density lipoprotein subfractions induces enhanced lysophosphatidylcholine production during oxidation in patients with heterozygous familial hypercholesterolaemia. Eur J Clin Invest 27: 595 - 602, 1997
  83. Katopodis KP, Elisaf MS, Pappas HA, Theodorou JCh, Milionis HJ, Bourantas KL, Siamopoulos KC. Renal abnormalities in patients with sickle cell - beta thalassemia. J Nephrol 10(3): 163 - 167, 1997
  84. Elisaf M, Milionis H, Tomos P, Siamopoulos KC. Multiple metabolic abnormalities in a patient with essential thrombocytosis. Platelets 8: 275 - 277, 1997
  85. Elisaf M, Milionis H, Siamopoulos KC. The mechanism of the increased serum urea levels in upper gastrointestinal hemorrhage. Eur J Intern Med  8: 127 - 129, 1997
  86. Milionis H, Elisaf M, Tsianos E. Post - cholocystectomy transient hundred - fold increase of CA 19 - 9. Eur J Gastroenterol Hepatol 9: 1013 - 1014, 1997
  87. Elisaf M, Bairaktari E, Tzallas C, Liberopoulos E, Siamopoulos KC. Lipid profile in Greek patients with heterozygous familial hypercholesterolemia. Hellenic Med J 1: 53 - 58,1997
  88. Elisaf M, Bouradas K, Siamopoulos KC. Pronounced electrolyte abnormalities in a patient with acute leukemia. Haematologica 82: 384, 1997
  89. Elisaf M, Siamopoulos KC. Mechanisms of hypophosphatemia in alcoholic patients. Int J Clin Pract 51: 501 - 503, 1997
  90. Milionis HJ, Elisaf MS, Drosos AA, Tsatsoulis AA. Concurrence of giant cell arteritis in a patient with De Quervain's thyroiditis. J Endocrinol 47: 760 - 761, 1997
  91. Elisaf M, Panteli K, Theodorou J, Siamopoulos KC. Fractional excretion of magnesium in normal subjects and in patients with hypomagnesemia. Magnesium Res 10: 315 - 320, 1997
  92. Siamopoulos KC, Elisaf M, Katopodis K. Iatrogenic hyperkalaemia - points to consider in diagnosis and management. Nephrol Dial Transplant  13: 2402 - 2406, 1997
  93. Elisaf M, Siamopoulos KC. Acid - base and electrolyte  abnormalities in patients with congestive heart failure. Clin Exp Cardiol 2: 140 - 144, 1997
  94. Elisaf M, Merkouropoulos M, Tsianos EV, Siamopoulos KC. Acid - base abnormalities in chronic alcoholic patients. Hellenic Journal of Gastroenterology 10: 59 - 63, 1997
  95. Milionis HJ, Bourantas KL, Bai M, Elisaf MS. Atypical presentation of post - partum visceral leishmaniasis. Am J Hematol 57: 89 - 90, 1998
  96. Terrovitou Ch, Milionis H, Elisaf M. Acute rhabdomyolysis after bezafibrate re - exposure. Nephron 78: 336 - 337, 1998
  97. Liberopoulos V, Elisaf M. Cotrimoxazole - induced hypouricemia. Clin Nephrol 49: 202, 1998
  98. Milionis H, Rondogianni D, Elisaf MS. Extramedullary haemopoiesis in a patient with β - thalassaemia trait. Intern J Heamatol 67: 87 - 89, 1998
  99. Milionis H, Elisaf M. Psoriasiform lesions as paraneoplastic manifestation in Hodgkin's disease. Ann Oncol 9: 449 - 452, 1998
  100. Elisaf M, Bairaktari E, Kalaitzidis R, Siamopoulos KC. Hypomagnesemia in alcoholic patients. Alcoholism Clin & Exp Res 22: 134, 1998
  101. Elisaf M, Kalaitzidis R, Siamopoulos KC. Multiple electrolyte abnormalities after pamidronate administration. Nephron 79: 337 - 339, 1998
  102. Bairaktari E, Elisaf M, Tsolas O, Siamopoulos KC. Serum Lp(a) levels in patients with moderate renal failure. Nephron 79: 367 - 368, 1998
  103. Milionis H, Tatsis C, Elisaf M. Retrosternal abscess as a prominent manifestation of staphylococcus aureus infection. Clin Infect Dis 26(6): 1462 - 1464, 1998
  104. Elisaf M, Bairaktari E, Nicolaides C, Fountzilas G, Tzallas C, Tsolas O, Siamopoulos KC, Pavlidis N. Do LH-RH analogues induce similar to tamoxifen effects on serum lipid parameters in premenopausal women with breast cancer? A prospective study. Nutr Metab Cardiovasc Dis 8: 101 - 106, 1998
  105. Dalekos GN, Boumba DS, Katopodis K, Zervou E, Sferopoulos G, Elisaf M, Tsianos EV, Siamopoulos KC. Absence of HCV viraemia in anti - HCV - negative haemodialysis patients. Nephrol Dial Transplant 13: 1804 - 1806, 1998
  106. Elisaf M, Bairaktari E, Katopodis K, Pappas M, Sferopoulos G, Tzallas C, Tsolas O, Siamopoulos KC. Effect of L - carnitine supplementation on lipid parameters in hemodialysis patients. Am J Nephrol 18: 416 - 421, 1998
  107. Dalekos GN, Zervou E, Elisaf M, Germanos N, Galanakis E, Bourantas K, Siamopoulos KC, Tsianos EV. Antibodies to hepatitis E virus among several populations in Greece: increased prevalence in an haemodialysis unit. Transfusion 38(6): 589 - 595, 1998
  108. Tselepis AD, Karabina S-AP, Elisaf M. PAF - acetylhydrolase activity in familial hypercholesterolemia. Eur J Clin Invest 28: 508 - 509, 1998
  109. Elisaf M, Katopodis K, Katsaraki A, Pappas M, Liberopoulos E, Siamopoulos KC. Serum magnesium levels in patients undergoing chronic ambulatory perioneal dialysis. Trace Elements & Electolytes 15: 155 - 158, 1998
  110. Elisaf M, Karabina S-A, Tselepis AD. High-density lipoprotein changes in patients with microvascular angina. Cardiovasc Res 40: 418, 1998
  111. Elisaf M, Siamopoulos KC. Hyperventilation after drug abuse: how are the observed acid - base and electrolyte abnormalities interpreted? Nephrol Dial Transplant  13: 2975 - 2976, 1998
  112. Milionis HJ, Bourantas CL, Elisaf MS. Sweet's syndrome as the presenting sign in a granulocytopenic patient with acute myelogenous leukemia. Eur J Intern Med 9: 183 - 184, 1998
  113. Elisaf M, Siamopoulos KC. Disorders of water, electrolyte and acid - base balance in alcoholic patients. Clin Nephrol 50: 390, 1998
  114. Efstathiadou Z, Elisaf M, Tsatsoulis A. Thyrotoxic hypokalaemic periodic paralysis. Report of two cases in Greek males. Eur J Intern Med 9: 293 - 295, 1998
  115. Milionis HJ, Siamopoulos KC, Elisaf MS. Lipoprotein(a), and apolipoprotein(a) phenotypes in patients with renal disease. Hellen Med J 2: 41 - 49, 1998
  116. Dalekos GN, Zervou EK, Elisaf M, Boumba DS, Katopodis K, Sferopoulos GS, Siamopoulos KC, Tsianos EV. Increased prevalence of markers of GBV-C/HGV infection in a selected cohort of haemodialysis patients negative for other blood - borne viruses. Nephrol Dial Transplant  14: 255 - 256, 1999
  117. Tselepis AD, Elisaf M, Besis S, Karabina S-AP, Chapman MJ, Siamopoulou A. Association of the inflammatory state in active juvenile rheumatoid arthritis with hypo - high - density lipoproteinemia and reduced lipoprotein - associated platelet - activating factor acetylhydrolase activity. Arthritis & Rheum 42: 373 - 383, 1999
  118. Milionis H, Elisaf M. Hyponatremia in a patient with hepatic cirrhosis. Nephrol Dial Transplant 14: 787 - 789, 1999
  119. Milionis HJ, Elisaf MS. Severe life - threatening hyperphosphatemia associated with tumor lysis in a patient with acute lymphoblastic leukemia. Am J Hematol 60: 252, 1999
  120. Elisaf M, Tselepis A, Siamopoulos KC. Selective imidazoline receptor agonists and lipid metabolism. Clin Chem Lab Med 37(2): 165, 1999
  121. Elisaf M, Karabina S-AP, Bairaktari E, Goudevenos JA, Siamopoulos KC, Tselepis AD. Increased pletelet reactivity to the aggregatory effect of platelet activating factor (PAF) in vitro in patients with heterozygous familial hypercholesterolemia. Platelets 10: 124 - 131, 1999
  122. Bairaktari ET, Tselepis AD, Milionis HJ, Elisaf MS. Lipoprotein (a) levels, apolipoprotein (a) phenotypes and thyroid autoimmunity. Eur J Endocrinol  140: 474 - 476, 1999
  123. Elisaf MS, Milionis HJ, Drosos AA. Hyponatremia due to inappropriate secretion of antidiuretic hormone in a patient with systemic lupus erythematosus. Clin Exp Rheumatol 17: 223 - 226, 1999
  124. Tsimihodimos V, Bairaktari E, Tzallas C, Miltiadous G, Liberopoulos E, Elisaf M. The incidence of thyroid function abnormalities in patients attending an outpatient lipid clinic. Thyroid 9: 365 - 368, 1999
  125. Elisaf M, Tsianos EV. Severe hypertriglyceridemia in a non - diabetic patient after alpha - interferon. Eur J Gastroenterol Hepatol 11: 463, 1999
  126. Milionis H, Elisaf M. Acid-base abnormalities in a patient with hepatic cirrhosis. Nephrol Dial Transplant 14 (6): 1599 - 1601, 1999
  127. Bairaktari ET, Tzallas CS, Tsimihodimos VK, Liberopoulos EN, Miltiadous GA, Elisaf MS. Comparison of the efficacy of atorvastatin and micronised fenofibrate in the treatment of mixed hyperlipidemia. J Cardiovasc Risk 6: 113 - 116, 1999
  128. Milionis HJ, Elisaf MS, Tselepis A, Bairaktari E, Karabina S-A, Siamopoulos KC. Apolipoprotein (a) phenotypes and lipoprotein (a) concentrations in patients with renal failure. Am J Kidney Dis 33: 1100 - 1106, 1999
  129. Papadopoulos G, Mieke S, Elisaf M. Assessment of the performances of three oscillometric blood pressure monitors for neonates using a simulator. Blood Pressure Monitoring 4: 27 - 33, 1999
  130. Konstantinidis A, Elisaf M, Panteli K, Constantopoulos S. Severe muscle weakness due to hypokalemia as a manifestation of small - cell carcinoma. Respiration 66: 269 - 272, 1999
  131. Elisaf MS, Kalaitzidis RG, Goudevenos JA, Katsaraki AE, Sideris DA, Siamopoulos KC. Blood pressure profile in patients with microvascular angina. Coronary Artery Dis 10: 257 - 259, 1999
  132. Elisaf MS, Milionis HJ, Siamopoulos KC. Lp(a) concentration and Apo(a) phenotypes in patients with moderate renal failure.Ann Intern Med 130: 1028, 1999
  133. Milionis H, Pritsivelis N, Elisaf M. Marked hypophosphatemia in a patient with acute leukemia. Nephron 83: 173, 1999
  134. Tselepis AD, Goudevenos JA, Tambaki AP, Michalis L, Stroumbis CS, Tsoukatos DC, Elisaf M, Sideris DA. Platelet aggregatory response to platelet activating factor (PAF), ex vivo, and PAF - acetylhydrolase activity in patients with unstable angina: effect of c7E3 Fab (abciximab) therapy. Cardiovasc Res 43: 183 - 191, 1999
  135. Elisaf M, Tsimichodimos V, Bairaktari E, Siamopoulos KC. Effect of micronized fenofibrate and losartan combination on uric acid metabolism in hypertensive patients with hyperuricemia. J Cardiovasc Pharmacol 34: 60 - 63, 1999
  136. Bairaktari E, Elisaf M, Katsaraki A, Tsimihodimos V, Tselepis AD, Siamopoulos KC, Tsolas O. Homogeneous HDL - cholesterol assay versus ultracentrifugation/dextran sulfate-Mg2+ precipitation and dextran sulfate-Mg2+ precipitation in healthy population and in hemodialysis patients. Clin Biochem 32: 339 - 346, 1999
  137. Liamis G, Bairaktari E, Elisaf M. Effect of fenofibrate on serum uric acid levels. Am J Kidney Dis 34: 594, 1999
  138. Milionis H, Elisaf M. Hyperkalemia in a patient with hepatic cirrhosis. Nephrol Dial Transplant 14: 2505 - 2506, 1999
  139. Elisaf M, Petris C, Bairaktari E, Karabina S-A, Tzallas C, Tselepis A, Siamopoulos KC. The effect of moxonidine on plasma lipid profile and on LDL subclass distribution. J Human Hypertens 13: 781 - 785, 1999
  140. Elisaf MS, Theodorou J, Pappas H, Papagalanis N, Katopodis K, Kalaitzidis R, Siamopoulos KC. Effectiveness and metabolic effects of perindopril and diuretics combination in primary hypertension. J Human Hypertens 13: 787 - 791, 1999
  141. Elisaf MS, Tomos PP, Milionis HJ, Siamopoulos KC. Prerenal azotemia in a diabetic patient with hyporeninemic hypoaldosteronism and autonomic neuropathy. Diabetes & Metabolism 25: 344 - 346, 1999
  142. Milionis HJ, Bourantas KL, Siamopoulos KC, Elisaf MS. Acid - base and electrolyte abnormalities in patients with acute leukemia. Am J Hematol 62: 201 - 207, 1999
  143. Milionis HJ, Elisaf MS, Karabina S-A, Bairaktari E, Tselepis AD, Siamopoulos KC. Plasma and Lp(a) associated PAF - acetylhydrolase activity in uremic patients undergoing dialysis procedures. Kidney Int 56: 2276 - 2285, 1999
  144. Milionis HJ, Elisaf MS, Mikhailidis DP. Platelet function and lipid - lowering intervention. Platelets 10: 357 - 367, 1999
  145. Elisaf MS, Siamopoulos KC. Hemorrhagic fever with renal syndrome - induced chronic renal dysfunction. Am J Nephrol 19: 709, 1999
  146. Bairaktari E, Hatzidimou K, Elisaf M. Lipoprotein (a) concentrations in Greek hyperlipidemic patients: relationship to serum lipid parameters. Eur Heart J 20: 1844, 1999
  147. Bairaktari E, Elisaf M, Katopodis K, Milionis H, Tzallas C, Katsaraki A, Siamopoulos K, Tsolas O. Lipoprotein (a), apolipoprotein (a) phenotypes and thyroid autoimmunity in patients with renal failure. Balk J Clin Lab 6: 5 - 11, 1999
  148. Liamis G, Elisaf M. Syndrome of inappropriate antidiuresis associated with multiple sclerosis. J Neurol Sci 172: 38 - 40, 2000
  149. Zalavras C, Dailiana Z, Elisaf M, Bairaktari E, Vlachogianopoulos P, Katsaraki A, Malizos K. Potential etiologic factors to the developement of osteonecrosis of the femoral head. Eur J Clin Invest  30: 215 - 221, 2000
  150. Milionis HJ, Elisaf MS, Mikhailidis DP. Treatment of dyslipidaemias in patients with established vascular disease: a revival of the fibrates. Curr Med Res Opin 16: 21 - 32, 2000
  151. Liamis G, Rizos E, Elisaf M. Reversible proximal tubular dysfunction in a patient with acute febrile illness and normal renal function: an evidence towards leptospirosis. Clin Nephrol 53: 316, 2000
  152. Kitsanou M, Andreopoulou E, Bai MK, Elisaf M, Drosos AA. Extensive lymphadenopathy as the first clinical manifestation in systemic lupus erythematosus. Lupus 9: 140 - 143, 2000
  153. Liamis G, Elisaf M. Hypokalemia, hypophosphatemia, and hypouricemia due to proximal renal tubular dysfunction in acute myeloid leukemia. Eur J Hematol 64: 277 - 278, 2000
  154. Elisaf M, Rizos E, Siamopoulos KC. Potassium excretion indices in the diagnostic approach to hypokalaemia. QJM 93: 318 - 319, 2000
  155. Kiortsis DN, Elisaf MS. Leisure - time physical activity and structural arterial properties of the common carotid artery. Atherosclerosis 149: 463, 2000
  156. Tomos P, Milionis H, Elisaf M. Eruptive xanthomata in a patient with hyperlipidemia type V. Resident & Staff 46: 20 - 32, 2000
  157. Milionis HJ, Skopelitou A, Elisaf M. Hypersensitivity syndrome caused by amitriptyline administration. Postgrad Med J 76: 361 - 363, 2000
  158. Elisaf M. Multiple risk factors in cardiovascular disease - Fifth International Symposium. IDrugs 3: 156 - 157, 2000
  159. Milionis H, Christou L, Elisaf M. Cutaneous manifestations in brucellosis: case report and review of the literature. Infection 28: 124 - 126, 2000
  160. Milionis HJ, Liamis G, Elisaf M. Hypernatremia in hospitalized patients: a sequel of inadvertent fluid administration. Arch Intern Med 160: 1541 - 1542, 2000
  161. Nakou K, Liamis G, Elisaf MS, Siamopoulos KC. Low normal potassium levels in acute renal failure: Evidence of leptospirosis. Infection 28: 196, 2000
  162. Liamis G, Alexandridis G, Bairaktari E, Elisaf M. Aminoglycosides - induced metabolic abnormalities. Ann Clin Biochem 37: 543 - 544, 2000
  163. Halperin G, Elisaf M, Leitersdorf E, Harats D. A new method for determination of serum cholestanol by high-performance liquid chromatography with ultraviolet detection. J Chromatogr B Biomed Sci Appl 742(2): 345 - 352, 2000
  164. Elisaf M. Olmesartan. Curr Opin Cardiovasc, Pulmonary & Renal Invest Drugs 2(4): 378 - 383, 2000
  165. Elisaf M, Bairaktari E, Pavlidis N. The influence of tamoxifen on serum triglycerides. Breast 9: 238, 2000
  166. Kiortsis DN, Elisaf MS. Correlates of lipoprotein(a) levels in a biracial cohort of young girls. J Pediatr 137: 438, 2000
  167. Miltiadous G, Elisaf M, Xenophontos S, Manoli P, Cariolou MA. Segregation of a novel LDLR gene mutation (I430T) with familial hypercholesterolaemia in a greek pedigree. Human Mutation 16: 277, 2000
  168. Kiortsis DN, Elisaf MS, Evagelou A. Adult cardiovascular risk factors in premature babies. Lancet 356: 938, 2000
  169. Elisaf MS, Nakou K, Liamis G, Pavlidis NA. Tamoxifen - induced severe hypertriglyceridemia and pancreatitis. Ann Oncol 11: 1067 - 1069, 2000
  170. Alexandridis G, Pappas G, Elisaf M. Rhabdomyolysis due to combination therapy with cerivastatin and gemfibrozil. Am J Med  109(3): 261 - 262, 2000
  171. Elisaf M. XII International Symposium on Atherosclerosis. IDrugs 3: 1162 - 1163, 2000
  172. Nikas S, Rizos E, Milionis H, Bairaktari E, Kalaitzidis R, Siamopoulos K, Elisaf M. The effects of the addition of losartan on uric acid metabolism in patients receiing indapamide. J Renin - Angiotensin - Aldosterone Synstem 1: 289 - 291, 2000
  173. Liamis G, Kalaitzidis R, Elisaf M. Hypernatremia during the correction of hypercalcemia. Nephron 86: 358, 2000
  174. Liamis G, Milionis H, Rizos E, Siamopoulos K, Elisaf M. Mechanisms of hyponatremia in alcoholics.  Alcohol  & Alcoholism 35: 612 - 616, 2000
  175. Milionis H, Elisaf M. Management of hypertension and dyslipidaemia in patients presenting with hyperuricaemia: case histories. Curr Med Res Opin 16: 164 - 170, 2000
  176. Kiortsis D, Evangelou A, Elisaf M. Lipoprotein (a) and chronic obstructive pulmonary disease. Atherosclerosis 152: 259, 2000
  177. Bairaktari E, Milionis H, Katopodis K, Tzallas C, Tselepis A, Tsolas O, Siamopoulos K, Elisaf M. Lipoprotein (a), apolipoprotein (a) phenotypes and thyroid autoimmunity in uremic patients. Endocrinologist 10: 383 - 388, 2000
  178. Rizos E, Alexandrides G, Elisaf M. Severe hypophosphatemia in a patient with acute pancreatitis. JOP 1: 204 - 207, 2000
  179. Kiortsis DN, Milionis H, Bairaktari E, Elisaf M. Efficacy of combination of atorvastatin and micronized fenofibrate in the treatment of severe mixed hyperlipidemia. Eur J Clin Pharmacol 56: 631 - 635, 2000
  180. Tsimihodimos V, Miltiadous G, Elisaf M. Therapy with statins is effective in some patients with homozygous familial hypercholesterolemia. Atherosclerosis 153: 527, 2000
  181. Liamis G, Gianoutsos C, Elisaf M. Hyperosmolar nonketotic syndrome with hypernatremia: how can we monitor treatment? Diabet Metab 26: 403 - 405, 2000
  182. Bairaktari E, Hatzidimou K, Tzallas C, Vinni M, Katsaraki A, Elisaf M, Tsolas O. Estimation of LDL cholesterol based on Friedewald formula and on Apo B levels. Clin Biochem 33: 549 - 555, 2000
  183. Goudevenos J, Tselepis AD, Vini MP, Michalis L, Tsoukatos DC, Elisaf M, Ninio E, Sideris DA. Platelet - associated and secreted PAF - acetylhydrolase activity in patients with stable angina. Sequential changes of the enzyme activity after angioplasty. Eur J Clin Invest 31: 15 - 23, 2001
  184. Bairaktari E, Elisaf M. Lp(a) concentrations in hyperapobetalipoproteinemia. Clin Chim Acta 303: 185, 2001
  185. Tsimichodimos V, Kalaitzidis R, Elisaf M. Hypouricemia in a patient with thyrotoxicosis. Eur J Endocrinol 144: 83, 2001
  186. Elisaf M, Katopodis K, Siamopoulos K. Renal abnormalities in sickle-cell β-thalassemia. Am J Haematol  66: 68 - 69, 2001
  187. Miltiadous G, Elisaf M, Bairaktari E, Xenophontos S, Manoli P, Cariolou M. Characterization and geographic distribution of the low density lipoprotein receptor (LDLR) gene mutations in Northwestern Greece. Human Mutation 17: 432 - 433, 2001
  188. Goudevenos JA, Bairaktari ET, Chatzidimou KG, Milionis HJ, Mikhailidis DP, Elisaf MS. The effect of atorvastatin on serum lipids, lipoprotein(a) and plasma fibrinogen levels in primary dyslipidaemia - a pilot study involving serial sampling. Curr Med Res Opin 16: 269 - 275, 2001
  189. Liberopoulos E, Miltiadous G, Elisaf M. Impressive lipid changes following hypolipidemic drug administration can unveil subclinical hyperthyroidism. Diabetes, Obesity & Metabolism 3: 97 - 98, 2001
  190. Milionis H, Liamis G, Elisaf M. Appropriate treatment of hypernatraemia in diabetic hyperglycaemic hyperosmolar syndrome. J Intern Med 249: 273 - 274, 2001
  191. Elisaf M, Kitsos G, Bairaktari E, Kalaitzidis R, Kalogeropoulos C, Psilas K. Metabolic abnormalities in patients with primary open-angle glaucoma. Acta Ophthalmol Scand 79: 129 - 132, 2001
  192. Milionis HJ, Liamis GL, Elisaf MS. Hyperosmolar syndrome in a patient with uncontrolled diabetes mellitus. Am J Kidney Dis 37(5): E41, 2001
  193. Milionis HJ, Liberopoulos EN, Elisaf MS. Tamoxifen - induced hypertriglyceridemia in association with diabetes mellitus. Diabet Metab 27(2): 160 - 163, 2001
  194. Liberopoulos E, Pavlidis N, Elisaf M. The effect of tamoxifen therapy on serum apolipoprotein A-I level is modified by the apolipoprotein E phenotype. Clin Biochem 34(2) : 161, 2001
  195. Katsanos KH, Elisaf M, Bairaktari E, Tsianos EV. Severe hypomagnesemia and hypoparathyroidism in kearns-sayre syndrome. Am J Nephrol 21(2): 150 - 153, 2001
  196. Tsimihodimos V, Kakafika A, Elisaf M. Fibrate treatment can increase serum creatinine levels. Nephrol Dial Transplant 16(6): 1301, 2001
  197. Bairaktari E, Liamis G, Tsolas O, Elisaf M. Partially reversible renal tubular damage in patients with obstructive jaundice. Hepatology 33(6): 1365 - 1369, 2001
  198. Alexandridis G, Elisaf M. The reply to: Combination therapy with cerivastatin and gemfibrozil causing rhabdomyolysis: is the interaction predictable? Am J Med  110(8): 669, 2001
  199. Milionis H, Bairaktari E, Liberopoulos E, Elisaf M. Atorvastatin versus micronized fenofibrate in the treatment of patients with mixed hyperlipoproteinemia. Am J Cardiol 88(2): 203, 2001
  200. Elisaf M. The treatment of coronary heaart disease: an update. Part 1: An overview of the risk factors for cardiovascular disease. Curr Med Res Opin 17(1): 18 - 26, 2001
  201. Miltiadous G, Tsimihodimos V, Bairaktari E, Elisaf M. Lipoprotein (a) levels in patients with homozygous familial hypercholesterolaemia. Atherosclerosis 157(1): 255 - 256, 2001 
  202. Mitliadous G, Cariolou MA, Elisaf M. Familial Hypercholesterolemia: Taking advantage of a founder effect for early diagnosis and treatment. Community Genet  4: 123 – 124, 2001
  203. Alexandridis G, Liamis G, Elisaf M. Reversible tubular dysfunction that mimicked fanconi's syndrome in a patient with anorexia nervosa. Int J Eat Dis 30(2): 227 - 230, 2001
  204. Iraklianou S, Melidonis A, Tournis S, Konstandelou E, Tsatsoulis A, Elisaf M, Sideris D. Postprandial leptin responses after an oral fat tolerance test: differences in type 2 diabetes. Diabetes Care 24(7): 1299 - 1301, 2001
  205. Milionis H, Elisaf M, Mikhailidis D. Statins for stroke prevention: is their use justified? Vasc Dis 4: 1 - 9, 2001
  206. Liamis G, Gianoutsos C, Elisaf M. Acute pancreatitis - induced hypomagnesemia. Pancreatology 1: 74 - 76, 2001
  207. Kakafika A, Tsimihodimos V, Elisaf M. Effect of atorvastatin on serum uric acid levels. Atherosclerosis 158: 255, 2001
  208. Alexandridis G, Elisaf M. Renal potassium handling in a patient with surreptitious vomiting. Nephrol Dial Transplant 16: 2275, 2001
  209. Katsouras CS, Karabina SA, Tambaki AP, Goudevenos JA, Michalis LK, Tsironis LD, Stroumbis CS, Elisaf MS, Sideris DA, Tselepis AD. Serum lipoprotein(a) concentrations and apolipoprotein(a) isoforms: association with the severity of clinical presentation in patients with coronary heart disease. J Cardiovasc Risk 8(5): 311 - 317, 2001
  210. Milionis HJ, Nikas S, Elisaf MS. Effects of losartan/diuretic combination treatment on serum uric acid levels in hypertensive patients. Am J Cardiol 88: 1084, 2001
  211. Milionis H, Elisaf M. Patients with alcohol problems. Ann Intern Med 135: 841, 2001
  212. Kiortsis D, Elisaf M. Effects of tamoxifen on endothelial function and cardiovascular risk factors in men with advanced atherosclerosis. Circulation 104: E146-E147, 2001
  213. Kakafika A, Liamis G, Elisaf M, Mikhailidis D. Effect of atorvatsatin on serum cretinine levels. Curr Med Res Opin 17: 230-231, 2001
  214. Kiortsis DN, Elisaf M. Serum Uric acid levels: a useful but not absolute marker of compliance with fenofibrate treatment. Fundam Clin Pharmacol 15: 401-403, 2001
  215. Efstathiadou Z, Bitsis S, Milionis H, Kukuvitis A, Bairaktari E, Elisaf M. Lipid profile in subclinical hypothyroidism: is L-thyroxine substitut beneficial? Eur J Endocrinol 145: 705-710, 2001
  216. Elisaf M, Liamis G, Liberopoulos E, Siamopoulos K. Mechanisms of hypocalcemia in alcoholic patients. Nephron 89: 459-460, 2001
  217. Milionis H, Tsapoga T, Elisaf M. Another report of acute rhabdomyolysis following cerivastatin monotherapy. Arch Intern Med 161: 2629-2630, 2001
  218. Elisaf M, Bairaktari E, Nikolaides C, Kakaidi B, Tzallas C, Katsaraki A, Pavlidis N. Effect of letrozole on the lipid profile in postmenopausal women with breast cancer. Eur J Cancer 37: 1510-1513, 2001
  219. Milionis HJ, Liamis GL, Elisaf MS. Plasma sodium changes in the hyperglycaemic state: Clinical aspects of pathophysiology and management. Int J Diabetes & Metabolism 9: 60 - 66, 2001
  220. Liberopoulos EN, Nonni AB, Tsianos EV, Elisaf MS. Possible ranitidine-induced cholestatic jaundice. Ann Pharmacother 36: 172, 2002
  221. Liberopoulos EN, Christides D, Elisaf M. Comparative effects of losartan and irbesartan on serum uric acid in hypertensive patients with hyperuricemia and gout. J Hypertens 20: 347, 2002
  222. Tsimihodimos V, Bairaktari E, Elisaf M. Fibrate-induced increase in serum urea and creatinine levels. Nephrol Dial Tranplant 17: 682, 2002
  223. Mitliadous G, Cariolou MA, Elisaf M. HDL cholesterol levels in patients with molecularly defined familial hypercholesterolemia. Ann Clin Lab Sci 32: 50-54, 2002
  224. Liberopoulos E, Karabina S-A, Tselepis A, Bairaktari E, Nicolaides C, Pavlidis N, Elisaf M. Are the effects of tamoxifen on the serum lipid profile modified by apolipoprotein E phenotypes? Oncology 62: 115-120, 2002
  225. Tsimihodimos V, Karabina S-A, Tambaki AP, Bairaktari E, Goudevenos JA, Chapman MJ, Elisaf M, Tselepis AD. Atorvastatin preferentially reduces LDL-associated platelet-activating factor acetylhydrolase activity in dyslipidemias of type IIA and type IIB. Arterioscler Thromb Vasc Biol 22: 306-311, 2002
  226. Milionis HJ, Alexandridis GE, Liberopoulos EN, Bairaktari ET, Goudevenos J, Elisaf MS. Hypomagnesemia and concurrent acid-base and electrolyte abnormalities in patinets with congestive heart failure. Eur J Heart Fail 4: 167-173, 2002
  227. Milionis H, Liamis G, Elisaf M. The hyponatremic patient: a systematic approach to laboratory diagnosis. CMAJ 166: 1056-1062, 2002
  228. Katsanos KH, Pappas CJ, Patsouras D, Michalis LK, Kitsios G, Elisaf M, Tsianos EV. Alarming atrioventricular block and mitral valve prolapse in the Kearns-Sayre syndrome. Int J Cardiol 83: 179-181, 2002
  229. Rizos E, Kostoula A, Elisaf M, Mikhailidis DP. Effect of ciprofibrate on C-reactive protein and fibrinogen levels. Angiology 53: 273-277, 2002
  230. Achimastos A, Liberopoulos E, Nikas S, Bairaktari E, Miltiadous G, Tsimihodimos V, Elisaf M. The effects of the addition of micronized fenofibrate on uric acid metabolism in patients receiving indapamide. Curr Med Res Opin 18: 59-63, 2002
  231. Tsimihodimos V, Miltiadous G, Bairaktari E, Elisaf M. Possible mechanisms of the fibrate-induced in serum creatinine. Clin Nephrol 57: 407-408, 2002
  232. Rizos E, Liamis G, Elisaf M. Multiple metabolic abnormalities in a patient with the syndrome of inappropriate antidiuresis. Nephron 91: 339-340, 2002
  233. Bairaktari E, Seferiadis K, Liamis G, Psihogios N, Tsolas O, Elisaf M. Rhabdomyolysis - related renal tubular damage studied by proton nuclear magnetic resonance spectroscopy of urine. Clin Chem  48: 1106 - 1109, 2002
  234. Liberopoulos E, Alexandridis G, Christidis D, Elisaf M. SIADH and hyponatremia with theophylline. Ann Pharmacother  36: 1180 - 1182, 2002
  235. Liberopoulos E, Bairaktari E, Elisaf M. Reversible proximal tubular dysfunction in a patient with acute febrile illness, marked hyperbilirubinemia and normal renal function: evidence of leptospirosis. Nephron  91: 532 - 533, 2002
  236. Elisaf M. Effects of fibrates on serum metabolic parameters. Curr Med Res Opin 18: 269 - 276, 2002
  237. Liberopoulos E, Alexandridis G, Bairaktari E, Elisaf M. Severe hypocholesterolemia with reduced serum lipoprotein(a) in a patient with visceral leishmaniasis. Ann Clin Lab Sci  32: 305 – 308, 2002
  238. Elisaf M, Liberopoulos E, Bairaktari E, Siamopoulos K. Hypokalaemia in alcoholic patients. Drug Alcohol Rev  21: 73 - 76, 2002
  239. Liberopoulos E, Miltiadous G, Elisaf M. Hypouricaemia as a marker of a generalized proximal tubular damage in alcoholic patients. Alcohol Alcohol  37: 472 - 474, 2002
  240. Miltiadous G, Hatzivassiliou M, Bashiardes E, Bairaktari E, Cariolou M, Elisaf M. Genetic polymorphisms of the apolipoprotein A - IV in a Greek population and their relation to plasma lipid and lipoprotein levels. Clin Genet  62: 208 - 213, 2002
  241. Ganotakis E, Tsimihodimos V, Bairaktari E, Rizos E, Athyros V, Seferiades C, Elisaf M. Effects of various fibrates on serum alkaline phosphatase activity. Atherosclerosis  165: 187, 2002
  242. Liamis G, Bairaktari E, Elisaf M. Hypokalemia due to Fanconi Syndrome in a patient with Obstructive Jaundice. Nephron   92: 711 - 712, 2002
  243. Elisaf M, Mikhailidis DP. Statins and renal function. Angiology 53: 493 - 502, 2002
  244. Liberopoulos E, Christidis D, Elisaf M. Marked hyperphosphataemia in a patient with diabetic ketoacidosis. Diabet Med 19: 885 - 886, 2002
  245. Milionis H, Dimos G, Tsiara S, Tsatsoulis A, Tsianos E, Elisaf M. Correspondence. Eur J Gastroenterol Hepatol  14: 1285 – 1286, 2002
  246. Liberopoulos EN, Drosos AA, Elisaf MS. Exacerbation of tuberculosis enteritis after treatment with inflimimaB. Am J Med  113: 615, 2002
  247. Liberopoulos E, Alexandridis G, Elisaf M. A tumor lysis - like syndrome during therapy of visceral leishmaniasis. Ann Clin Lab Sci  32: 419 - 421, 2002
  248. Rizos E, Milionis H, Pavlidis N, Elisaf M. Acpuired icthyosis: a paraneoplastic skin manifestation of Hodgkin's disease. Lancet Oncol  3: 727, 2002
  249. Rizos E, Bairaktari E, Ganotakis E, Tsimihodimos V, Mikhailidis DP, Elisaf M. Effect of ciprofibrate on lipoproteins, fibrinogen, renal function, and hepatic enzymes. J Cardiovasc Rharmacol Ther  7: 219 - 226, 2002
  250. Assimakopoulos D, Patrikakos G, Fotika C, Elisaf M. Benign migratory glossitis or geographic tongue: an enigmatic oral lesion.  Am J Med   113: 751 - 755, 2002
  251. Milionis HJ, Elisaf MS. Hyponatremia and SIADH – Two oft he authors respond. Can Med Assoc J 167:450-450, 2002
  252. Roukos DH, Briasoulis E, Michos KM, Elisaf M, Agnantis NJ, Kappas AM. Breast and gastric cancer: comparing what we learn. Ann Surg Oncol  10: 92 - 94, 2003
  253. Miltiadous G, Papakostas J, Chasiotis G, Seferiadis K, Elisaf M. Statins and homocysteine. Atherosclerosis  166: 199 - 200, 2003
  254. Milionis H, Dimos G, Elisaf M. Severe hyperkalaemia in association with diabetic ketoacidosis in a patient presenting with severe generalized muscle weakness. Nephrol Dial Transplant  18: 198 - 200, 2003
  255. Miltiadous G, Anthopoulou A, Elisaf M. Acute pancreatitis possibly associated with combined salicylate and atorvastatin therapy. JOP  4: 20-21, 2003
  256. Kostoula A, Elisaf M. Fibrates and C-reactive protein. Clin Chim Acta  328: 197, 2003
  257. Telford M, Elisaf M. Clinical pharmacokinetics of fenofibrate. Curr Med Res Opin  19: 139-140, 2003
  258. Alexandridis G, Liberopoulos E, Elisaf M. Aminoglycoside-induced reversible tubular dysfunction. Pharmacology  67: 118-20, 2003
  259. Kolovou GD, Daskalova DCh, Hatzivassiliou M, Yiannakouris N, Pilatis ND, Elisaf M, Mikhailidis DP, Cariolou MA, Cokkinos DV. The epsilon 2 and 4 alleles of apolipoprotein E and ischemic vacular events in the Greek population-implications for the interpretation of similar studies. Angiology  54: 51-8, 2003
  260. Tsimihodimos V, Kakafika A, Tambaki AP, Bairaktari E, Chapman MJ, Elisaf M, Tselepis AD. Fenofibrate induces HDL-associated PAF-AH but attenuates enzyme activity associated with apoB-containing lipoproteins. J Lipid Res  44: 927-34, 2003
  261. Robin X, Phelip JM, Milionis H, Tsatsoulis A, Tsianos E, Elisaf M. Unexplained hypertransaminasaemia: a clue to the diagnosis of Addison’s disease. Eur J Gastroenterol & Hepatology  15: 929-930, 2003
  262. Karkabounas S, Kiortsis DN, Zelovitis J, Skafida P, Demetzos C, Malamas M, Elisaf M, Evangelou A. Effects of Cupressus sempervirens cone extract on lipid parameters in Wistar rats. In Vivo  17: 101-3, 2003
  263. Milionis HJ, Goudevenos J, Seferiadis K, Elisaf M. Associations between body mass index and risks in elderly patietns with a first-ever acute ischemic stroke. Arch Intern Med  163: 980, 2003
  264. Liberopoulos EN, Liamis GL, Elisaf MS. Possible cefotaxime-induced Stevens-Johnson syndrome. Ann Pharmacother  37: 812-4, 2003
  265. Bairaktari ET, Kakafika AI, Pritsivelis H, Hatzidimou KG, Tsianos EV, Seferiadis KI, Elisaf MS. Hypouricemia in individuals admitted to an inpatient hospital-based facility. Am J Kidney Dis  41: 1225-32, 2003
  266. Athyros VG, Papageorgiou AA, Symeonidis AN, Elisaf M. Non-high density lipoprotein cholesterol and coronary events during long-term treatment. Atherosclerosis  168: 397-8, 2003
  267. Milionis HJ, Efstathiadou Z, Tselepis AD, Bairaktari ET, Tsironis LD, Tsatsoulis A, Elisaf MS. Lipoprotein (a) levels and apolipoprotein (a) isoform size in patients with subclinical hypothyroidism: effect of treatment with levothyroxine. Thyroid  13: 365-9, 2003
  268. Rizos E, Bairaktari E, Kostoula A, Hasiotis G, Achimastos A, Ganotakis E, Elisaf M, Mikhailidis DP. The combination of nebivolol plus pravastatin is associated with a more beneficial metabolic profile compared to that of atenolo plus pravastatin in hypertensive patients with dyslipidemia: a pilot study. J Cardiovasc Pharmacol Ther  8: 127-34, 2003
  269. Kakafika AI, Xenofontos S, Tsimihodimos V, Tambaki AP, Lourida ES, Kalaitzidis R, Cariolou MA, Elisaf M, Tselepis AD. The PON1 M55L gene polymorphism is associated with reduced HDL-associated PAF-AH activity. J Lipid Res  44: 1919-26,2003
  270. Tsimihodimos V, Karabina SA, Tambaki A, Bairaktari E, Achimastos A, Tselepis A, Elisaf M. Effect of atorvastatin on the concentration, relative distribution, and chemical composition of lipoprotein subfractions in patients with dyslipidemias of type IIA and IIB. J Cardiovasc Pharmacol  42: 304-10, 2003
  271. Agnantis NJ, Roukos DH, Paraskevaidis E, Elisaf M. Cyclin E: a new biologic prognostic marker for breast cancer? Gastric Breast Cancer 2: 9-11, 2003
  272. Kiortsis DN, Nikas S, Hatzidimou K, Tsianos E, Elisaf MS. Lipid-lowering drugs and serum liver enzymes: the effects of body weight and baseline enzyme levels. Fundam Clin Pharmacol  17: 491-4, 2003
  273. Liberopoulos E, Tolis C, Bai M, Efremidis S, Pavlidis N, Elisaf M. Succesful treatment of human immunosufficiency virus-related Castleman’s disease: a case report and literature review. Oncology  65: 182-6, 2003
  274. Katopodis KP, Koliousi EL, Andrikos EK, Pappas MV, Elisaf MS, Siamopoulos KC. Magnesium homeostasis in patients undergoing continuous ambulatory peritoneal dialysis: role of the dialysate magnesium concentration. Artif Organs  27: 853-7, 2003
  275. Milionis HJ, Papakostas J, Kakafika A, Chasiotis G, Seferiadis K, Elisaf MS. Comparative effects of atorvatatin, simvastatin, and fenofibrate on srum homocysteine levels in patients with primary hyperlipidemia. J Clin Pharmacol  43: 825-30, 2003
  276. Konitsiotis S, Glantzouni A, Argyropoulou MI, Tsapoga T, Elisaf M, Efremidis SC. Acute spontaneous spinal subdural haematomas in a patient with essential thromocythaemia. J Neurol  250: 1109-11, 2003
  277. Tsiara S, Elisaf M, Jagroop IA, Mikhailidis DP. Platelets as predictors of vascular risk: is ther a practical index of platelet activity? Clin Appl Thromb Hemost  9: 177-90, 2003
  278. Milionis HJ, Elisaf MS, Mikahilidis DP. The effects of lipid-regulating therapy on haemostatic parameters. Curr Pharm Des  9: 2425-43, 2003
  279. Tsiara S, Elisaf M, Mikhailidis DP. Influence of smoking on predictors of vascular disease. Angiology  54: 507-30, 2003
  280. Liberopoulos EN, Elisaf MS. Could apolipoprotein E polymorphisms be hidden behind the relation between bone mineral density and atherosclerosis in hemodialysis patients? Osteoporos Int  14: 957, 2003
  281. Tsiara S, Elisaf M, Mikhailidis DP. Early vascular benefits of statin therapy. Curr Med Res Opin  19: 540-56, 2003
  282. Elisaf M, Tselepis A. Effect of hypolipidemic drugs on lipoprotein –associated platelet activating factor acetylhydrolase implication for atherosclerosis. Biochem Pharmacol  66: 2069-2073, 2003
  283. Milionis HJ, Miltiadous GA, Cariolou M, Elisaf MS. Pinpoint skin lesions in a familial hypercholesterolaemia homozygote. Acta Paediatr  92: 1109-10, 2003
  284. Athyros VG, Papageorgiou AA, Elisaf M, Mikhailidis DP; GREACE Study Collaborative Group. Statins and renal function in patients with diabetes mellitus. Curr Med Res Opin  19: 615-7, 2003
  285. Rizos E, Dimos G, Milionis HJ, Elisaf MS. Temporal arteritis masquerading as chronic myelomonocytic leukemia. Clin Exp Rheumatol  21: 685-6, 2003
  286. Milionis HJ, Mittari V, Exarchakos G, Kalaitzidis R, Skevas AT, Elisaf MS. Lipoprotein (a) and acute-phase response in patients with vestibular neuronitis. Eur J Clin Invest  33: 1045-50, 2003
  287. Karabina SA, Pappas H, Miltiadous G, Bairaktari E, Christides D, Tselepis A, Elisaf M, Siamopoulos K. Compositional lipoprotein changes and low-density lipoprotein susceptibility to oxidation in chronic renal failure patients with heavy proteinuria. Nephron Clin Pract.  95: 77-83, 2003
  288. Miltadous G, Mikhailidis DP, Elisaf M. Acid-base and electrolyte abnormalities observed in patients receiving cardiovascular drugs. J Cardiovasc Pharmacol Ther  8: 267-76, 2003
  289. Pappas G, Liberopoulos E, Tsianos E, Elisaf M. Enterococcus casseliflavus bacteremia. Case report and literature review. J Infect  48: 206-8, 2003
  290. Rizos E, Liberopoulos E, Kosta P, Efremidis S, Elisaf M. Carbofuran-induced acute pancreatitis. JOP  5: 44-7, 2004
  291. Liberopoulos E, Siamopoulos K, Elisaf M. Apolipoprotein E and renal disease. Am J Kidney Dis  43: 223-233, 2004
  292. Mitsios JV, Tambaki AP, Abatzis M, Biris N, Sakarellos-Daitsiotis M, Sakarellos C, Soteriadou K, Goudevenos J, Elisaf M. Effect of synthetic peptides corresponding to residues 313-332 of the alphaIIb subunit on platelet activation and fibrinogen binding to alphaIIbbeta 3. Eur J Biochem  271: 855-62, 2004
  293. Daskalopoulou SS, Mikhailidis DP, Athyros VG, Papageorgiou AA, Elisaf M. Fenofibrate and losartan. Ann Rheum Dis  63: 469-70, 2004
  294. Athyros VG, Elisaf M, Mikhailidis DP. Diabetic dyslipidaemia-the case for using statins. The British Journal of Diabetes & Vascular Disease 4:  57-58, 2004
  295. Mitsios JV, Papathanasiou AI, Rodis FI, Elisaf M, Goudevenos JA, Tselepis AD. Atorvastatin does not affect the antiplatelet potency of clopidogrel when it is administered concomitantly for 5 weeks in patients with acute coronary syndromes. Circulation  109: 1335-8, 2004
  296. Athyros VG, Elisaf M, Papageorgiou AA, Symeonidis AN, Pehlivanidis AN, Bouloukos VI, Milionis HJ, Mikhailidis DP, GREACE Study Collaborative Group. Effect of statins versus untreated dyslipidemia on serum uric acid levels in patients with coronary heart disease: a subgroup analysis of the Greek Atorvastatin and Coronary –heart- disease Evaluation (GREACE) study. Am J Kidney Dis  43: 589-99, 2004
  297. Tsimihodimos V, Kostoula A, Kakafika A, Bairaktari E, Tselepis AD, Mikhailidis DP, Elisaf M. Effect of fenofibrate on serum inflammatory markers in patients with high triglyceride values. J Cardiovasc Pharmacol Ther  9: 27-33, 2004
  298. Liberopoulos E, Apostolou F, Elisaf M. Serum lipid profile in patients with severe leptospirosis. Nephrol Dial Transplant  19: 1328-9, 2004
  299. Athyros VG, Mikhailidis DP, Papageorgiou AA, Symeonidis AN, Mercouris BR, Pehlivanidis A, Bouloukos VI, Elisaf M, GREACE Collaborative Group. Effect of atorvastatin on high density lipoprotein cholesterol and its relationship with coronary evetns: a subgroup analysis of the Greek atorvastatin and Coronary –heart-disease Evaluation (GREACE) Study. Curr Med Res Opin  20: 627-37, 2004
  300. Liberopoulos EN, Miltiadous GA, Cariolou M, Kaliaitzidis R, Siamopoulos KC, Elisaf MS. Influence of apolipoprotein E polymorphisms on serum creatinine levels and precicted glomerular filtration rate in healthy subjects. Nephrol Dial Transplant  19: 2006-12, 2004
  301. Tsironis LD, Mitsios JV, Milionis HJ, Elisaf M, Tselepis AD. Effect of lipoprotein (a) on platelet activation induced by platelet –activating factor: role of apolipoprotein (a) and endogenous PAF-acetylhydrolase. Cardiovasc Res  63: 130-8, 2004
  302. Milionis HJ, Elisaf MS. Metabolic alkalosis in patients with renal failure. Nephrol Dial Transplant  19: 1932, 2004
  303. Daskalopoulou SS, Athyros VG, Elisaf M, Mikhailidis DP. Uric acid levels and vascular disease. Curr Med Res Opin  20: 951-4, 2004
  304. Athyros VG, Mikhailidis DP, Papageorgiou AA, Symeonidis AN, Pehlivanidis AN, Bouloukos VI, Elisaf M. The effect of statins versus untreated dyslipidemia on renal function in patients with coronary heart disease. A subgroup analysis of the Greek atorvastatin and coronary heart disease evaluation (GREACE) study. J Clin Pathol  57: 728-34, 2004
  305. Athyros VG, Mikhailidis DP, Papageorgiou AA, Bouloukos VI, Pehlivanidis AN, Symeonidis AN, Elisaf M. Effect of statins and ACE inhibitors alone and in combination on clinical outcome in patients with coronary heart disease. J Hum Hypertens  18: 781-788, 2004
  306. Liberopoulos EN, Miltiadous GA, Elisaf MS. Alcohol intake, serum uric acid concentrations and risk of gout. Lancet  364: 246-7, 2004
  307. Mitliadous G, Liamis G, Metafratzi Z, Vartholomatos G, Koliatis N, Elisaf M. Subclavian vein thrombosis: A case report and review of the literature. Int J Angiology  13: 45-48, 2004
  308. Milionis HJ, Athyros VG, Elisaf M, Mikhailidis DP. The Greace study collaborative group. Structured care with atorvastatin in patients with type 2 diabetes mellitus and coronary heart disease. Br J Diabetes Vasc Dis  4: 94-97, 2004
  309. Liberopoulos EN, Miltiadous GA, Cariolou M, Tselepis AD, Siamopoulos KC, Elisaf MS. The influence of serum apolipoprotein E concentration and polymorphism on serum lipid parameters in hemodialysis patients. Am J Kidney Dis  44: 300-8, 2004
  310. Balafa OC, Karabina SA, Pappas CA, Elisaf M, Tselepis AD, Siamopoulos KC. Urine of patients with nephrotic syndrome contains the plasma type of PAF-acetylhydrolase associated with lipoproteins. Nephrol Physiol  97: 45-52, 2004
  311. Tambaki AP, Rizos E, Tsimihodimos V, Tselepis AD, Elisaf M. Effects of antihypertensive and hypolipidemic drugs on plasma and high-density lipoprotein-associated platelet activating factor-acetylhydrolase activity. J Cardiovasc Pharmacol Ther  9: 91-5, 2004
  312. Katopodis KP, Elisaf M, Balafa O, Nikolopoulos P, Bairaktari E, Katsaraki A, Siamopoulos KC. Influence of the Type of Membrane and Heparin in serum lipid parameters during a dialysis session: A pilot study. Am J Nephrol 24: 469 - 473, 2004
  313. Voulgari PV, Pappas GA, Liberopoulos EN, Elisaf M, Skopouli FN, Drosos AA. Visceral leishmaniasis resembling systemic lupus erythematosus. Ann Rheum Dis  63: 1348-9, 2004
  314. Bairaktari ET, Tzallas C, Kalientzidou M, Tselepis AD, Siamopoulos KC, Seferiadis KI, Elisaf MS. Evaluation of alternative calculation methods for determing low-density lipoprotein cholesterol in hemodialysis patients. Clin Biochem  37: 937-40, 2004
  315. Tsimihodimos V, Elisaf M, Tselepis A, Tambaki A, Bairaktari E. Effect of fenofibrate on the concentration and relative distribution of LDL subfractions in patients with combined dyslipidemia. Letters in Drug Desigh & Discovery  1: 380-383, 2004
  316. Daskalopoulou SS, Athyros VG, Elisaf M, Mikhailidis D. The impact of serum uric acid on cardiovascular outcomes in the LIFE study. Kidney Int  66: 1714-5, 2004
  317. Milionis HJ, Kakafika AI, Tsouli SG, Athyros VG, Bairaktari ET, Seferiadis KI, Elisaf MS. Effects of statin treatment on uric acid homeostasis in patients with primary hyperlipidemia. Am Heart  148: 635-40, 2004
  318. Liberopoulos E, Miltiadous G, Hatzivassiliou M, Ayrton N, Bairaktari E, Cariolou M, Elisaf M. Apolipoprotein E polymorphism in northwestern Greece: frequency and effect on lipid parameters. Ann Clin Lab Sci  34: 347-54, 2004
  319. Tsironis LD, Katsouras CS, Lourida ES, Mitsios JV, Goudevenos J, Elisaf M, Tselepis AD. Reduced PAF-acetylhydrolase activity associated with Lp(a) in patients with coronary artery disease. Atherosclerosis  177: 193-201, 2004
  320. Athyros VG, Elisaf M, Mikhailidis DP. Undertreatment of dyslipidaemia in Greece. Atherosclerosis  177: 215-6, 2004
  321. Miltiadous G, Cariolou M, Elisaf M. Genetic polymorphisms affecting the phenotypic expression of patients with molecularly defined familial hypercholesterolaemia. Atherosclerosis  177: 217, 2004
  322. Mitsios JV, Papathanasiou AI, Rodis FI, Elisaf M, Goudevenos Ja, Tselepis AD. Clinical significnance of the atorvastatin –clopidogrel drug-drug interaction-response. Circulation  110: E66-E67, 2004
  323. Mitsios JV, Papathanasiou AI, Rodis FI, Elisaf M, Goudevenos JA, Tselepis AD. Potential statin-clopidogrel interaction requires more study-Response. Circulation  110: E68, 2004
  324. Tzamaloukas AH, Rohrscheib M, Ing TS, Siamopoulos KC, Elisaf MS, Spalding CT. Serum tonicity, extracellular volume and clinical manifestations in symptomatic dialysis-associated hyperglycemia treated only with insulin. Int J Artif Organs  27: 751-8, 2004
  325. Milionis HJ, Kakafika AI, Tsouli SG, Athyros VG, Bairaktari ET, Seferiadis KI, Elisaf MS. Effects of statin treatment on uric acid homeostasis in patients with primary hyperlipidemia. Am Heart J  148: 635-640, 2004
  326. Daskalopoulou SS, Mikhailidis DP, Elisaf M. Prevention and treatment of the metabolic syndrome. Angiology  55: 589-612, 2004
  327. Liberopoulos EN, Papavasiliou E, Miltiadous GA, Cariolou M, Siamopoulos KC, Tselepis AD, Elisaf MS. Alterations of paraoxonase and platelet-activating factor acetylhydrolase activities in patients on peritoneal dialysis. Perit Dial Int  24: 580-9, 2004
  328. Athyros VG, Mikhailidis DP, Papageorgiou AA, Didangelos TP, Ganotakis ES, Symeonidis AN, Daskalopoulou SS, Kakafika AI, Elisaf M; METS-GREECE Collaborative Group. Prevalence of atherosclerotic vascular disease among subjects with the metabolic syndrome with or without diabetes mellitus: the METS-GREECE Multicentre Study. Curr Med Res Opin  20: 1691-1701, 2004
  329. Athyros VG, Elisaf M, Papageorgiou AA. Pathogenesis and treatment of kidney disease and hypertension- Effect of statins versus untreated dyslepidemia on serum uric acid levels in patients with coronary heart disease: A subgroup analysis of the GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study. Am J Kidney Dis 43; 589-599, 2004
  330. Tsimihodimos V, Miltiadous G, Daskalopoulou SS, Mikhailidis DP, Elisaf MS. Fenofibrate: metabolic and pleiotropic effects. Curr Vasc Pharmacol  3: 87-98, 2005
  331. Rizos E, Tambaki AP, Gazi I, Tselepis AD, Elisaf M. Lipoprotein-associated PAF-acetyhydrolase activity in subjects with the metabolic syndrome. Prostaglandins Leukot Essent Fatty Acids  72: 203-9, 2005
  332. Miltiadous G, Xenophontos S, Cariolou M, Elisaf M. ACE insertion deletion polymorphisms and effectiveness of statin therapy. Atherosclerosis  178: 405, 2005
  333. Milionis HJ, Liberopoulos E, Goudevenos J, Bairaktari ET, Seferiadis K, Elisaf MS. Risk factors for first-ever acute ischemic non-embolic stroke in elderly individuals. Int J Cardiol  99: 269-75, 2005
  334. Milionis HJ, Tselepis AD, Tsatsoulis A, Elisaf MS. Emerging cardiovascular risk factors in suclinical hypothyroidism: Lack of change after restoration of euthyroidism. Metabolism  54: 559, 2005
  335. Liberopoulos EN, Daskalopoulou SS, Mikhailidis DP, Wierzbicki AS, Elisaf MS. A review of the lipid-related effects of fluvastatin. Curr Med Res Opin  21: 231-44, 2005
  336. Kiortsis DN, Filippatos TD, Elisaf MS. The effects of orlistat on metabolic parameters and other cardiovascular risk factors. Diabetes Metab  31: 15-22, 2005
  337. Filippatos TD, Kiortsis DN, Liberopoulos EN, Mikhailidis DP, Elisaf MS. A review of the metabolic effects of sibutramine. Curr Med Res Opin  21: 457-68, 2005
  338. Tsouli SG, Kiortsis DN, Argyropoulou MI, Mikhailidis DP, Elisaf MS. Pathogenesis, detection and treatment of Achilles tendon xanthomas. Eur J Clin Invest  35: 236-44, 2005
  339. Tzamaloukas AH, Rohrscheib M, Ing TS, Siamopoulos KC, Qualls C, Elisaf MS, Vanderjagt DJ, Spalding CT. Serum potassium and acid-base parameters in severe dialysis-associated hyperglycemia treated with insulin therapy. Int J Artif Organs  28: 229-36, 2005
  340. Bairaktari ET, Seferiadis KI, Elisaf MS. Evaluation of methods for the measurement of low-density lipoprotein cholesterol. J Cardiovasc Pharmacol Ther  10: 45-54, 2005
  341. Athyros VG, Mikhailidis DP, Papageorgiou AA, Bouloukos VI, Pehlivanidis AN, Symeonidis AN, Kakafika AI, Daskalopoulou SS, Elisaf M. Effect of statins and aspirin alone and in combination on clinical outcome in dyslipidaemic patients with coronary heart disease. A subgroup analysis of the GREACE study. Platelets  16: 65-71, 2005
  342. Kalaitzidis R, Tsimohodimos V, Bairaktari E, Siamopoulos KC, Elisaf M. Disturbances of phosphate metabolism: another feature of metabolic syndrome. Am J Kidney Dis  45: 851-858, 2005
  343. Mitliadous G, Xenophontos S, Bairaktari E, Ganotakis M, Cariolou M, Elisaf M. Genetic and environmental factors affecting the response to statin therapy in patients with molecularly defined familial hypercholesterolemia. Pharmacogenet Genomics  15: 219-225, 2005
  344. Liberopoulos EN, Athyros VG, Elisaf MS, Mikhailidis DP. New-onset diabetes after transplantation. Lancet  365: 1766, 2005
  345. Liberopoulos EN, Miltiadous GA, Athyros VG, Ganotakis M, Cariolou M, Bairaktari E, Elisaf MS. Effect of apolipoprotein E polymorphism on serum uric acid levels in healthy subjects. J Investig Med  53: 116-122, 2005
  346. Milionis HJ, Tambaki AP, Kanioglou CN, Elisaf MS, Tselepis AD, Tsatsoulis A. Thyroid substitution therapy induces high-density lipoprotein-associated platelet –activating factor-acetylhydrolase in aptients with suclinical hypothyroidism: a potential antiatherogenic effect. Thyroid  15: 455-460, 2005
  347. Milionis HJ, Rizos E, Goudevenos J, Seferiadis K, Mikhailidis DP, Elisaf MS. Components of the metabolic syndrome and risk for first-ever acute ischaemic nonembolic stroke in elderly subjects. Stroke  36: 1372-1376, 2005
  348. Miltiadous G, Hatzivassiliou M, Liberopoulos E, Bairaktari E, Tselepis A, Cariolou M, Elisaf M. Nutr Metab Cardiovasc Dis  15: 219-224, 2005
  349. Liberopoulos EN, Tsouli S, Elisaf MS. Apolipoprotein E polymorphism and the risk of acute nephropathy after cardiac surgery. Ann Thorac Surg  80: 382-383, 2005
  350. Liberopoulos EN, Athyros VG, Elisaf MS, Mikhailidis DP. Targets for low-density lipoprotein cholesterol levels in patients with stable coronary heart disease: where are we now after the ‘’treating to new targets’’ (TNT) trial? Hell J Cardiol  46: 161-164, 2005
  351. Liberopoulos EN, Elisaf M. Clinical use of nebivolol in the treatment of chronic heart failure. Hell J Cardiol  46: 208-211, 2005
  352. Mitsios JV, Papathanasiou AI, Elisaf M, Goudevenos JA, Tselepis AD. The inhibitory potency of clopidogrel on ADP-induced platelet activation is not attenuated when it is co-administered with atorvastatin (20mg/day) for 5 weeks in patients with acute coronary syndromes. Platelets  16: 287-292, 2005
  353. Milionis HJ, Daskalopoulou SS, Elisaf M, Mikhailidis DP. The predictive value of lipid markers in vascular disease. Curr Pharm Des  11: 2209-2224, 2005
  354. Athyros VG, Elisaf M, Mikhailidis DP. Inflammatory markers and the metabolic syndrome. Atherosclerosis  183: 1878, 2005
  355. Kiortsis DN, Tsouli S, Lourida ES, Xydis V, Argyropoulou MI, Elisaf M, Tselepis AD. Lack of association between carotid intima-media thickness and PAF-acetylhydrolase mass and activity in patients with primary hyperlipidemia. Angiology  56: 451-458, 2005
  356. Athyros VG, Ganotakis ES, Elisaf M, Mikhailidis DP. The prevalence of the metabolic syndrome using the National Cholesterol Educational Program and International Diabetes Federation definitions. Curr Med Res Opin  21: 1157-1159, 2005
  357. Milionis HJ, Elisaf MS. Reply to Al-Shaer, is atorvastatin more appropriate to use in combination with niacin than simvastatin in patients with the metabolic syndrome? (Am Heart J 2005;149: e17.) Am Heart J  150: e7, 2005
  358. Athyros VG, Mikhailidis DP, Papageorgiou AA, Didangelos TP, Peletidou A, Kleta D, Karagiannis A, Kakafika AI, Tziomalos K, Elisaf M. Targeting vascular risk in patients with metabolic syndrome but without diabetes. Metabolism  54: 1065-1074, 2005
  359. Rizos E, Dimos G, Liberopoulos EN, Elisaf MS, Drosos AA. Cryoglobulinemic purpura in visceral leishmaniasis. Rheumatol Int  25: 469-471, 2005
  360. Milionis HJ, Elisaf MS. Therapeutic management of hyperglycaemic hyperosmolar syndrome. Expert Opin Pharmacother  2005;6: 1841-1849, 2005
  361. Liberopoulos EN, Elisaf MS. Diagnosis of the metabolic syndrome: which definition should we use? Hell J Cardiol  46: 258-262, 2005
  362. Kalambokis G, Milionis H, Elisaf M, Tsianos EV. Terlipressin avoids hemodialysis in the treatment of refractory hyperkalemia associated with renal dysfunction in cirrhosis. Am J Med  118: 1051-1052, 2005
  363. Milionis HJ, Gazi IF, Filippatos TD, Tzovaras V, Chasiotis G, Goudevenos J, Seferiadis K, Elisaf MS. Starting with rosuvastatin in primary hyperlipidemia-Is there more than lipid lowering? Angiology  56: 585-92, 2005
  364. Milionis HJ, Filippatos TD, Loukas T, Bairaktari ET, Tselepis AD, Elisaf MS. Serum lipoprotein (a) levels and apolipoprotein (a) isoform size and risk for first-ever acute ischaemic nonembolic stroke in elderly individuals. Atherosclerosis  187: 170-6, 2006
  365. Gazi I, Lourida ES, Filippatos T, Tsimihodimos V, Elisaf M, Tselepis AD. Lipoprotein-associated phospholipase A2 activity is a marker of small, dense LDL particles in human plasma. Clin Chem  51: 2264-73, 2005
  366. Milionis HJ, Kalantzi KJ, Goudevenos JA, Seferiadis K, Mikhailidis DP, Elisaf MS. Serum uric acid levels and risk for acute ischaemic non-embolic stroke in elderly subjects. J Intern Med  258: 435-41, 2005
  367. Liberopoulos EN, Mikhailidis DP, Elisaf MS. Diagnosis and management of the metabolic syndrome in obesity. Obes Rev  6: 283-96, 2005
  368. Danielides V, Milionis HJ, Karavasilis V, Briasoulis E, Elisaf M. Syndrome of inappropriate antidiuretic hormone secretion due to recurrent oral cancer. B-ENT  1: 151-3, 2005
  369. Liberopoulos EN, Elisaf MS, Tselepis AD, Archimandritis A, Kiskinis D, Cokkinos D, Mikhailidis DP. Upper gastrointestinal haemorrhage complicating antiplatelet treatment with aspirin and/or clopidogrel: where we are now? Platelets  17: 1-6, 2006
  370. Filippatos TD, Milionis HJ, Elisaf MS. Alterations in electrolyte equilibrium in patients with acute leukemia. Eur J Haematol  75: 449-60, 2005
  371. Diamantopoulos EJ, Athyros VG, Yfanti GK, Migdalis EN, Elisaf M, Vardas PE, Manolis AS, Karamitsos DT, Ganotakis ES, Hatseras D; OLYMPIC Study Group. Angiology  56: 731-41, 2005
  372. Filippatos TD, Kiortsis DN, Liberopoulos EN, Georgoula M, Mikhailidis DP, Elisaf MS. Effect of orlistat, micronized fenofibrate and their combination on metabolic parameters in overweight and obese patients with the metabolic syndrome: the FenOrli study. Curr Med Res Opin  21: 1997-2006, 2005
  373. Daskalopoulou SS, Tzovaras V, Mikhailidis DP, Elisaf M. Effect on serum uric acid levels of drugs prescribed for indications other than treating hyperuricaemia. Curr Pharm Des  11: 4161-75, 2005
  374. HJ, Elisaf MS, Mikhailidis DP. Treatment of dyslipidemias in patients with established vascular disease: a revival of the fibrates. Curr Med Res Opin  16: 21-32, 2000
  375. Athyros VG, Ganotakis ES, Bathianaki M, Monedas I, Goudevenos IA, Papageorgiou AA, Papathanasiou A, Kakafika AI, Mikhailidis DP, Elisaf M; MetS-Greece Collaborative Group. Awareness, treatment and control of the metabolic syndrome and its components: a multicentre Greek study. Hellenic J Cardiol  46: 380-6, 2005
  376. Liamis G, Kalogirou M, Saugos V, Elisaf M. Therapeutic approach in patients with dysnatremias. Nephrol Dial Transplant  21: 1564-9, 2006
  377. Liberopoulos EN, Tsouli S, Mikhailidis DP, Elisaf MS. Preventing type 2 diabetes in high risk patients: an overview of lifestyle and pharmacological measures. Curr Drug Targets  7: 211-28, 2006
  378. Liberopoulos EN, Mikhailidis DP, Athyros VG, Elisaf MS. The effect of cholesterol-lowering treatment on renal function. Am J Kidney Dis  47: 561, 2006
  379. Milionis HJ, Liberopoulos EN, Achimastos A, Elisaf MS, Mikhailidis DP. Statins; another class of antihypertensive agents? J Hum Hypertens  20: 320-35, 2006
  380. Kiortsis DN, Argyropoulou MI, Tsouli SG, Xydis V, Elisaf MS. Correlation of Achilles tendon thickness evaluated by ultrasonography with carotid intima-media thickness in patients with familial hypercholesterolemia. Atherosclerosis  2006: 228-9, 2006
  381. Gazi I, Tsimihodimos V, Filippatos TD, Saugos VG, Bairaktari ET, Tselepis AD, Elisaf M. LDL cholesterol estimation in patients with metabolic syndrome. Lipid Health Dis  5: 8, 2006
  382. Kalambokis G, Milionis HJ, Economou M, Tsianos EV, Elisaf MS. Prominent hypophosphatemia due to proximal tubulopathy mimicking Fanconi’s syndrome in a patient with obstructive jaundice. Clin Nephrol  65: 306-7, 2006
  383. Tsouli SG, Liberopoulos EN, Kiortsis DN, Mikhailidis DP, Elisaf MS. Combined treatment with angiotensin –converting enzyme inhibitors and angiotensin II receptor blockers: a review of the current evidence. J Cardiovasc Pharmacol Ther  11: 1-15, 2006
  384. Athyros VG, Mikhalidis DP, Didangelos TP, Giouleme OI, Liberopoulos EN, Karagiannis A, Kakafika AI, Tziomalos K, Burroughs AK, Elisaf MS. Effect of multifactorial treatment on non-alcoholic fatty liver disease in metabolic syndrome: a randomized study. Curr Med Res Opin  22: 873-83, 2006
  385. Katopodis KP, Andrikos EK, Gouva CD, Bairaktari ET, Nikolopoulos PM, Takouli LK, Tzallas CS, Elisaf MS, Pappas MV, Siamopoulos KC. Sevelamer hydrochloride versus aluminum hydroxide: effect on serum phosphorus and lipids in capd patients. Perit Dial Int  26: 320-7, 2006
  386. Gazi I, Tsimihodimos V, Filippatos T, Bairaktari E, Tselepis AD, Elisaf M. Concentration and relative distribution of low-density lipoprotein subfractions in patients with metabolic syndrome defined according to the National Cholesterol Education Program criteria. Metabolism  55: 885-91, 2006
  387. Milionis HJ, Rizos E, Kostapanos M, Filippatos TD, Gazi IF, Ganotakis ES, Goudevenos J, Mikhailidis DP, Elisaf MS. Treating to target patients with primary hyperlipidemia: comparison of the effects of ATOrvastatin and ROSuvastatin (the ATOROS study). Curr Med Res Opin  22: 1123-31, 2006
  388. Athyros VG, Ganotakis ES, Elisaf MS, Liberopoulos EN, Goudevenos IA, Karagiannis A; for the GREECE-METS Collaborative Group. Prevalence of vascular disease in metabolic syndrome using three proposed definitions. Int J Cardiol  2006
  389. Tsouli SG, Kiortsis DN, Lourida ES, Xydis V, Tsironis LD, Argyropoulou MI, Elisaf M, Tselepis AD. Autoantibody titers against OxLDL are correlated with Achilles tendon thickness in aptients with familial hypercholesterolemia. J Lipid Res  47: 2208-14, 2006
  390. Gazi I, Liberopoulos EN, Saugos VG, Elisaf M. Beneficial effects of omega-3 fatty acids: the current evidence. Helenic J Cardiol  47: 223-31, 2006
  391. Liberopoulos EN, Athyros VG, Elisaf MS, Mikhalidis DP. Statins for non-alcoholic fatty liver disease: a new indication? Aliment Pharmacol Ther  24: 698-9, 2006
  392. Filippatos TD, Gazi IF, Liberopoulos EN, Athyros VG, Elisaf MS, Tselepis AD, Kiortsis DN. The effect of orlistat and fenofibrate, alone or in combination, on small dense LDL and lipoprotein-associated phospholipase A(2) in obese patients with metabolic syndrome. Atherosclerosis  2006
  393. Miltiadous G, Saugos V, Cariolou M, Elisaf MS. Plasma lipoprotein(a) levels and LDL-cholesterol lowering response to statin therapy in patients with heterozygous familial hypercholesterolemia. Ann Clin Lab Sci 36: 353-5, 2006
  394. Rizos EC, Milionis HJ, Elisaf MS. Fever with rash following zolendronic acid and administration. Clin Exp Rheumatol 24: 455, 2006
  395. Tsouli SG, Liberopoulos EN, Mikhailidis DP, Athyros VG, Elisaf MS. Elevated serum uric acid levels in metabolic syndrome: an active component or an innocent bystander? Metabolism  55: 1293-301, 2006
  396. Athyros VG, Mikhailidis DP, Liberopoulos EN, Kakafika AI, Karagiannis A, Papageorgiou AA, Tziomalos K, Ganotakis ES, Elisaf M. Effect of statin treatment on renal function and serum uric acid levels and their relation to vascular events in patients with coronary heart disease and metabolic syndrome: A subgroup analysis of the GREek Atorvastatin and Coronary heart disease Evaluation (GREACE) Study. Nephrol Dial Transplant  22: 118-27, 2006
  397. Gazi IF, Elisaf M. LDL-cholesterol calculation formulas in patient swith or without the metabolic syndrome. Int J Cardiol  119(3):414-5, 2007
  398. Kostapanos MS, Milionis HJ, Gazi I, Kostara C, Bairaktari ET, Elisaf M. Rosuvastatin increases alpha-1 microglobulin urinary excretion in patients with primary dyslipidemia. J Clin Pharmacol  46: 1337-43, 2006
  399. Christidis DS, Liberopoulos EN, Kakafika AI, Miltiadous GA, Cariolou M, Ganotakis ES, Mikhailidis DP, Elisaf MS. The effect of apolipoprotein E polymorphism on the response to lipid-lowering treatment with atorvastatin or fenofibrate. J Cardiovasc Pharmacol Ther  11: 211-21, 2006
  400. Tsouli SG, Kiortsis DN, Xydis V, Argyropoulou MI, Elisaf M, Tselepis AD. Antibodies against various forms of mildly oxidized low-density lipoprotein are not associated with carotid intima-media thickness in patients with primary hyperlipidemia. Angiology  57: 615-22, 2006
  401. Gazi IF, Filippatos TD, Tsimihodimos V, Saougos VG, Liberopoulos EN, Mikhailidis DP, Tselepis AD, Elisaf M. The hypertriglyceridemic waist phenotype is a predictor of elevated levels of small, dense LDL cholesterol. Lipids  41: 647-54, 2006
  402. Kiortsis DN, Filippatos TD, Mikhailidis DP, Elisaf MS, Liberopoulos EN. Statin-associated adverse effects beyond muscle and liver toxicity. Atherosclerosis  195(1):7-16, 2007
  403. Karagiannis A, Athyros VG, Papageorgiou A, Tziomalos K, Elisaf M. Should atenolol still be recommended as first-line therapy for primary hypertension? Hellenic J Cardiol  47: 298-307, 2006
  404. Gazi IF, Liberopoulos EN, Athyros VG, Elisaf M, Mikhailidis DP. Statins and solid organ transplantation. Curr Pharm Des  12: 4771-4783, 2006
  405. Spirou A, Rizos E, Liberopoulos EN, Kolaitis N, Achimastos A, Tselepis AD, Elisaf M. Effect of barnidipine on blood pressure and serum metabolic parameters in patients with essential hypertension: a pilot study. J Cardiovasc Pharmacol Ther  11: 256-261, 2006
  406. Gazi IF, Tsimihodimos V, Tselepis AD, Elisaf M, Mikhailidis DP. Clinical importance and therapeutic modulation of small dense low-density lipoprotein particles. Expert Opin Biol Ther  7: 53-72, 2007
  407. Karagiannis A, Mikhailidis DP, Athyros VG, Kakafika AI, Tziomalos K, Liberopoulos EN, Florentin M, Elisaf M. The role of renin-angiotensin system inhibition in the treatment of hypertension in metabolic syndrome; are all the angiotensin receptor blockers equal? Expert Opin Ther Targets  11: 191-205, 2007
  408. Katopodis KP, Koliousi E, Gouva C, Balafa O, Bairaktari E, Ikonomou M, Elisaf MS, Siamopoulos KC. Acute effect of heparin on lipid parameters in patients on renal replacement therapy. ASAIO J  53: 46-49, 2007
  409. Athyros VG, Karagiannis A, Kakafika A, Elisaf M, Mikhailidis DP. Statins and renal function. Is the compound and dose making a difference? Nephrol Dial Transplant  22: 963-4, 2007
  410. Athyros VG, Karagiannis A, Liberopoulos EN, Elisaf M, Mikhailidis DP. Statin treatment may be beneficial to both the kidneys and the heart. Perit Dial Int  27: 215-6, 2007
  411. Diakou MC, Liberopoulos EN, Mikhailidis DP, Tsianos EV, Burroughs AK, Elisaf MS. Pharmacological treatment of non-alcoholic steatohepatitis: the current evidence. Scand J Gastroenterol  42: 139-47, 2007
  412. Athyros VG, Mikhailidis DP, Kakafika AI, Karagiannis A, Hatzitolios A, Tziomalos K, Ganotakis ES, Liberopoulos EN, Elisaf M. Identifying and attaining LDL-C goals: mission accomplished? Next target: ne therapeutic options to raise HDL-C levels. Curr Drug Targets  8: 483-8, 2007
  413. Kostapanos MS, Liberopoulos EN, Goudevenos JA, Mikhailidis DP, Elisaf MS. Do statins have an antiarrhythmic activity? Cardiovasc Res  75(1):10-20, 2007
  414. Milionis HJ, Kostapanos MS, Liberopoulos EN, Goudevenos J, Athyros VG, Mikhailidis DP, Elisaf MS. Different definitions of the metabolic syndrome and risk of first-ever acute ischaemic non-embolic stroke in elderly subjects. Int J Clin Pract  61: 545-51, 2007
  415. Christidis DS, Liberopoulos EN, Kakafika AI, Miltiadous GA, Liamis GL, Kakaidi B, Tselepis AD, Cariolou MA, Elisaf MS. Effect of paraoxonase 1 polymorphisms on the response of lipids and lipoprotein-associated enzymes to treatment with fluvastatin. Arch Med Res  38: 403-10, 2007
  416. Tsimihodimos V, Gazi I, Kostara C, Tselepis AD, Elisaf M. Plasma lipoproteins and triacylglycerol are predictors of small, dense LDL particles. Lipids  42: 403-9, 2007
  417. Liamis G, Christidis D, Alexandridis G, Bairaktari E, Madias NE, Elisaf M. Uric acid homeostasis in the evaluation of diuretic-induced hyponatremia. J Investig Med  55: 36-44, 2007
  418. Filippatos TD, Liberopoulos EN, Kostapanos M, Gazi IF, Papavasiliou EC, Kiortsis DN, Tselepis AD, Elisaf MS. The effects of orlistat and fenofibrate, alone or in combination, on high-density lipoprotein subfractions and pre-beta 1-HDL levels in obese patients with metabolic syndrome. Diabetes Obes Metab  10(6):476-83, 2008
  419. Psihogios NG, Gazi IF, Elisaf MS, Seferiadis KI, Bairaktari ET. Gender-related and age-related urinalysis of healthy subjects by NMR-based metabonomics. NMR 21(3):195-207,2008
  420. Economou M, Milionis H, Filis S, Baltayannis G, Christou L, Elisaf M, Tsianos E. Baseline cholesterol is associated with the response to antiviral therapy in chronic hepatitis C. J Gastroenterol Hepatol  23(4):586-91, 2008
  421. Kalogirou M, Tsimihodimos V, Gazi I, Filippatos T, Saougos V, Tselepis AD, Mikhailidis DP, Elisaf M. Effect of ezetimibe monotherapy on the concentration of lipoprotein subfractions in patients with primary dyslipidemia. Curr Med Res Opin  23: 1169-76, 2007
  422. Elisaf M. Acid-base balance-electrolytes quiz-case 1. Archives of Hellenic Medicine  24: 632, 2007
  423. Milionis HJ, Liberopoulos EN, Elisaf MS, Mikhailidis DP. Analysis of antihypertensive effects of statins. Curr Hypertens Rep  9: 175-83, 2007
  424. Liamis G, Mitrogianni Z, Liberopoulos EN, Tsimihodimos V, Elisaf M. Electrolyte disturbances in patients with hyponatremia. Intern Med  46: 685-90, 2007
  425. Filippatos TD, Derdemezis CS, Kiortsis DN, Tselepis AD, Elisaf MS. Increased plasma levels of visfatin /pre-B cell colonyenhancing factor in obese and overweight patients with metabolic syndrome. J Endocrinol Invest  30: 323-6, 2007
  426. Kiortsis DN, Tsouli S, Filippatos TD, Konitsiotis S, Elisaf MS. Effects of sibutramine and orlistat on mood in obese and overweight subjects: A randomized study. Nutr Metab Cardiovasc Dis  18(3):207-10, 2008
  427. Milionis HJ, Filippatos TD, Derdemezis CS, Kalantzi KJ, Goudevenos J, Seferiadis K, Mikhaildis DP, Elisaf MS. Excess body weight and risk of first-ever acute ischaemic non-embolic stroke in elderly subjects. Eur J Neurol  14: 762-769, 2007
  428. Panoulas VF, Milionis HJ, Douglas KM, Nightngale P, Kita MD, Klocke R, Elisaf MS, Kitas GD. Association of serum uric acid with cardiovacular disease in rheumatoid arthritis. Rheumatology  46: 1466-70, 2007
  429. Saougos VG, Tambaki AP, Kalogirou M, Kostapanos M, Gazi IF, Wolfert RL, Elisaf M, Tselepis AD. Differential effect of hypolipidemic drugs on lipoprotein-associated phospholipase A2. Arterioscler Thromb Vasc Biol  27: 2236-43, 2007
  430. Korantzopoulos P, Elisaf M, Milionis HJ. Multifactorial intervention in metabolic syndrome targeting at prevention of chronic kidney disease ready for prime time? Nephrol Dial Transplant  22: 2768-74, 2007
  431. Tsouli SG, Liberopoulos EN, Goudevenos JA, Mikhailidis DP, Elisaf MS. Should a statin be prescribed to every patient with heart failure? Heart Fail Rev  13(2):211-25, 2008
  432. Panoulas VF, Douglas KM, Milionis HJ, Stavropoulos-Kalinglou A, Nightingale P, Kita MD, Tselios AL, Metsios GS, Elisaf MS, Kitas GD. Prevalence and associations of hypertenion and its control in patients with rheumatoid arthritis. Rheumatology  46: 1477-82, 2007
  433. Tsimihodimos V, Psychogios N, Kakaidi V, Bairaktari E, Elisaf M. Salicylate-induced proximal tubular dysfunction. Am J Kidney Dis  50: 463-7, 2007
  434. Kostapanos MS, Milionis HJ, Filippatos TD, Nakou ES, Bairaktari ET, Tselepis AD, Elisaf MS. A 12-week, prospective, open-label analysis of the effect of rosuvastatin on triglyceride-rich lipoprotein metabolism in patients with primary dyslipdemia. Clin Ther  29: 1403-14, 2007
  435. Tzovaras V, Chatzikyriakidou A, Bairaktari E, Liberopoulos EN, Georgiou I, Elisaf M. Absence of SLC22A12 gene mutations in Greek Caucasian patients with primary renal hypouricaemia. Scand J Clin Lab Invest  67: 589-95, 2007
  436. Kostapanos MS, Derdemezis CS, Filippatos TD, Milionis HJ, Kiortsis DN, Tselepis AD, Elisaf M. Effect of rosuvastatin treatment on plasma visfatin levels in patients with primary hyperlipidemia. Eur J Pharmacol  14;578(2-3):249-52, 2008
  437. Liamis G, Tsimihodimos V, Doumas M, Spyrou A, Bairaktari E, Elisaf M. Clinical and laboratory characteristics of hypernatremia in an internal medicine clinic. Nephrol Dial Transplant  23(1):136-43, 2008
  438. Panoulas VF, Douglas KM, Milionis HJ, Nightingale P, Kita MD, Klocke R, Metsios GS, Stavropoulos –Kalinoglou A, Elisaf MS, Kitas GD. Serum uric acid is independently associated with hypertension in patients with rheumatoid arthritis. J Hum Hypertens 22(3):177-82, 2008
  439. Gazi IF, Milionis HJ, Filippatos TD, Tsimihodimos V, Kostapanos MS, Doumas M, Tselepis AD, Elisaf M. Hypertriglyceridaemic waist phenotype criteria and prevalent metabolic ttriad in women. Diabetes Metab Res Rev  24(3):223-30, 2008
  440. Tzamaloukas AH, Ing TS, Siamopoulos KC, Rohrscheib M, Elisaf MS, Raj DS, Murata Gh. Body fluid abnormalities in severe hyperglycemia in patients on chronic dialysis: theoretical analysis. J Diabetes Complications 21: 374-80, 2007
  441. Florentin M, Liberopoulos EN, Elisaf MS. Sibutramine-associated adverse effects: a practical guide for its safe use. Obes Rev  9(4):378-87, 2008
  442. Panoulas VF, Douglas KM, Stavropoulos-Kalinoglou A, Metsios GS, Nightngale P, Kita MD, Elisaf MS, Kitas GD. Long-term exposure to medium-dose glucocorticoid therapy associates with hypertension in patients with rheumatoid arthritis. Rheumatology  47: 72-5, 2008
  443. Filippatos TD, Derdemezis CS, Gazi IF, Nakou ES, Mikhailidis DP, Elisaf MS. Orlistat –associated adverse effects and drug interactions: a critical review. Drug Saf  31: 53-65, 2008
  444. Kostapanos MS, Milionis HJ, Saougos VG, Lagos KG, Kostara C, Bairaktari ET, Elisaf MS. Dose-dependent effect of rosuvastatin treatment on urinary protein excretion. J Cardiovasc Pharmacol Ther  12: 292-7, 2007
  445. Filippatos TD, Derdemezis CS, Gazi IF, Lagos K, Kiortsis DN, Tselepis AD, Elisaf MS. Increased plasma visfatin levels in subjects with the metabolic syndrome. Eur J Clin Invest  38: 71-2, 2008
  446. Florentin M, Liberopoulos EN, Elisaf M. Ezetimibe-associated adverse effects: what the clinician needs to know. Int J Clin Pract  62: 88-96, 2008
  447. Tzamaloukas AH, Ing TS, Siamopoulos KC, Rohrscheib M, Elisaf MS, Raj DS, Murata GH. Body fluid abnormalities in severe hyperglycemia in patients on chronic dialysis: review of published reports. J Diabetes Complications  22: 29-37, 2008
  448. Georgiadis AN, Voulgari PV, Argyropoulou MI, Alamanos Y, Elisaf M, Tselepis AD, Drosos AA. Early treatment reduces the cardiovascular risk factors in newly diagnosed rheumatoid arthritis patients. Semin Arthritis Rheum  38(1):13-9, 2008
  449. Milionis HJ, Kostapanos MS,Vakalis K, Theodorou I, Bouba I, Kalaitzidis R, Georgiou I, Elisaf MS, Siamopoulos KC. Impact of renin-angiotensin-aldosterone system genes on the treatment response of patients with hyperetension and metabolic syndrome. J Renin Angiotensin Aldosterone Syst  8: 181-189, 2007
  450. Miltiadous G, Christidis D, Kalogirou M, Elisaf M. Causes and mechanisms of acid-base and electrolyte abnormalities in cancer patients. Eur J Intern Med  19: 1-7, 2008
  451. Athyros VG, Liberopoulos EN, Mikhailidis DP, Papageorgiou AA, Ganotakis ES, Tziomalos K, Kakafika AI, Karagiannis A, Lambropoulos S, Elisaf M. Association of drinking pattern and alcohol beverage type with the prevalence of metabolic syndrome, diabetes, coronary heart disease, stroke, and peripheral arterial disease in a Mediterranean cohort. Angiology  58: 689-97, 2007
  452. Milionis HJ, Elisaf MS, Mikhailidis DP. Lipid abnormalities and cardiovascular risk in the elderly. Curr Med Res Opin  24(3):653-7, 2008
  453. Protopsaltis I, Korantzopoulos P, Milionis HJ, Koutsovasilis A, Nikolopoulos GK, Dimou E, Kokkoris S, Brestas P, Elisaf M, Melidonis A. Metabolic syndrome and its components as predictors of ischemic stroke in type 2 diabetic patients. Stroke  39: 1036-8, 2008
  454. Liberopoulos EN, Mikhailidis DP, Elisaf M. Colesevelam hydrochloride in clinical practice: a new approach in the treatment of hypercholesterolaemia. Curr Med Res Opin  2008
  455. Florentin M, Liberopoulos EN, Mikhailidis DP, Elisaf MS. Fibrate-associated adverse effects beyond muscle and liver toxicity. Curr Pharm Des  14: 547-87, 2008
  456. Tzovaras V, Liberopoulos EN, Zioga A, Pavlidis N, Elisaf M. Persistent erythema multiforme in a patient with extrahepatic cholangiocarcinoma. Oncology  73: 127-129, 2008
  457. Tsimihodimos V, Gazi I, Kalaitzidis R, Elisaf M, Siamopoulos KC. Increased serum ferritin concentrations and liver enzyme activities in patients with metabolic syndrome. Metab Syndr Relat Disord  4: 196-203, 2006
  458. ONTARGET Investigators, Yusuf S, Teo KK, Pogue J, Dyal L, et al. Telmisartan, ramipril , or both in patients at high risk for vascular events. N Engl J Med  358: 1547-59, 2008
  459. Rizos CV, Liberopoulos E, Mikhailidis DP, Elisaf MS. Pleiotropic effects of thiazolidinediones. Expert Opin Pharmacother  9: 1087-108, 2008
  460. Rother J, Alberts MJ, Touze E, Mas JL, Hill MD, Michel P, Bhatt DL, Aichner FT, Goto S, Matsumoto M, Ohman EM, Okada Y, Uchiyama S, D’Agostino R, Hirsch AT, Wilson PW, Steg PG , REACH Registry Investigators. Risk factor profile and management of cerebrovascular patients in the REACH Registry. Cerebrovac Dis 25: 366-74, 2008
  461. Kostapanos MS, Milionis HJ, Elisaf MS. An Overview of the Extra-Lipid effects of Rosuvastatin. J Cardiovasc Pharmacol Ther  13: 157-74, 2008
  462. Liamis G, Milionis H, Elisaf M. A review of Drug-Induced hyponatremia. Am J Kidney Dis  52: 144-53, 2008
  463. Nakou ES, Filippatos TD, Georgoula M, Kiortsis DN, Tselepis AD, Mikhailidis DP, Elisaf M. The effect of orlistat and ezetimibe, alone or in combination , on serum LDL and small dense LDL cholesterol levels in overweight and obese patients with hypercholesterolemia. Curr Med Res Opin  24: 1919-29, 2008
  464. Florentin M, Liberopoulos EN, Mikhailidis DP, Elisaf MS. Sitagliptin in clinical practice : a new approach in the treatment of type 2 diabetes. Expert Opin Pharmacother  9: 1705-20, 2008
  465. Kostapanos MS, Milionis HJ, Lagos KG, Rizos CB, Tselepis AD, Elisaf MS. Baseline triglyceride levels and insulin sensitivity are major determinants of the increase of LDL particle size and buoyancy induced by rosuvastatin treatment in patients with primary hyperlipidemia. Eur J Pharmacol  590: 327-32, 2008
  466. Derdemezis C, Filippatos T, Tselepis A, Mikhailidis D, Elisaf M. Effects of ezetimibe, either alone or in combination with atorvastatin , on serum visfatin levels: a pilot study. Expert Opin Pharmacother  9: 1829-37, 2008
  467. Panoulas VF, Douglas KM, Smith JP, Taffe P, Stavropoulos-Kalinoglou A, Toms TE, Elisaf MS, Nightngale P, Kitas GD. Polymorphisms of the endothelin-1 gene associate with hypertension in patients with rheumatoid arthritis. Endothelium  15: 203-12, 2008
  468. Liamis G, Milionis H, Elisaf M. Blood pressure drug therapy and electrolyte disturbances. Int J Clin Pract 62;1572-80, 2008
  469. Nakou ES, Liberopoulos EN, Milionis HJ, Elisaf MS. The role of C-reactive protein in atherosclerotic cardiovascular disease: an overview. Curr Vasc Pharmacol  6: 258-70, 2008
  470. Florentin M, Liberopoulos E, Filippatos T, Kostara C, Tselepis A, Mikhailidis D, Elisaf M. Effect of rimonabant, micronised fenofibrate and their combination on cardiometabolic risk factors in overweight/obese patients: a pilot study. Expert Opin Pharmacother  9: 2741-2750, 2008
  471. Papadopoulos CG, Voulgari PV, Zioga A, Miltiadous GA, Nicolopoulos P, Elisaf MS, Drosos AA. Significant improvement of axillary artery stenosis in a 67 year-old woman with giant cell arteritis. Clin Exp Rheumatol  26: S151-2, 2008
  472. Tzamaloukas AH, Ing TS, Siamopoulos KC, Raj DS, Elisaf MS, Rohrscheib M, Murata GH. Pathophysiology and management of fluid and electrolyte disturbances in patients on chronic dialysis with severe hyperglycemia. Semin Dial  21: 431-9, 2008
  473. Athyros VG, Kakafika AI, Papageorgiou AA, Pagourelias ED, Savvatianos SD, Elisaf M, Karagiannis A, Tziomalos K, Mikhailidis DP. Statin-induced increase in HDL-C and renal function in coronary heart disease patients. Open Cardiovasc Med J  1: 8-14, 2008
  474. Filippatos TD, Tsimihodimos V, Kostapanos M. Small dense LDL cholesterol and apolipoproteins C-II and C-III in non-diabetic obese subjects with metabolic syndrome. Arch Med Sci 4;263-269, 2008
  475. Rizos EC, Spyrou A, Liberopoulos EN, Papapvasiliou EC, Saougos V, Tselepis AD, Elisaf M. Effects of eprosartan on serum metabolic parameters in patients with essential hypertension. Open Cardiovasc Med J  1: 22-6, 2008
  476. Liamis G, Milionis H, Elisaf M. In Reply to ‘Drug-induced hyponatremia adding to the list’ and ‘Tramadol-induced hyponatremia’. Am J Kidney Dis 52; 1027-1027, 2008
  477. Lagos KG, Filippatos TD, Tsimihodimos V, Gazi IF, Rizos C, Tselepis AD, Mikhailidis DP, Elisaf M. Alterations in the high density lipoprotein phenotype and HDL-associated enzymes in subjects with metabolic syndrome. Lipids  44: 9-16, 2009
  478. Filippatos TD, Derdemezis CS, Elisaf Ms. Effects of orlistat, alone or combined with hypolipidemic drugs on cardiovascular risk factors. Clin Lipidol 4; 331-341, 2009
  479. Liamis G, Milionis H, Elisaf M. In reply to ‘’drug-induced hyponatremia adding to the list’’ and ;’’tramadol-induced hyponatremia’’ . Am J kidney Dis  52: 1027, 2008
  480. Christidis D, Katopodis K, Nesseris I, Dimou S, Tsili A, Siamopoulos K, Elisaf M. A 40-year-old man with polyneuropathy is admitted because of edema , arterial hypertension, and dyslipidemia. Archives of Hellenic Medicine  25: 823-832, 2008
  481. Elisaf M, Agouridis A. Acid-base balance electrolyte quiz-Case 7. Archives of Hellenic Medicine  25: 833, 2008
  482. Elisaf M, Agouridis A. Acid-base balance electrolyte quiz-Case 6. Archives of Hellenic Medicine  25: 685, 2008
  483. Elisaf M, Agouridis A. Acid-base balance electrolyte quiz-Case 5. Archives of Hellenic Medicine  25: 539, 2008
  484. Elisaf M, Agouridis A. Acid-base balance electrolyte quiz-Case 4. Archives of Hellenic Medicine  25: 397, 2008
  485. Elisaf M, Agouridis A. Acid-base balance electrolyte quiz-Case 3. Archives of Hellenic Medicine  25: 255, 2008
  486. Elisaf M. Acid-base balance electrolytes quiz-Case 2. Archives of Hellenic Medicine  25: 121, 2008
  487. Liamis G, Svarna E, Gusia A, Bafa M, Efremidis S, Elisaf M. A patient with rheumatoid arthritis, fever and weight loss.  Archives of Hellenic Medicine  25: 111-120, 2008
  488. Liberopoulos EN, Florentin M, Mikhailidis DP, Elisaf MS. Compliance with lipid-lowering therapy and its impact on cardiovascular morbidity and mortality. Expert Opin Drug Saf  7: 717-25, 2008
  489. Filippatos TD, Liberopoulos EN, Pavlidis N, Elisaf MS, Mikhailidis DP. Effects of hormonal treatment in lipids in patients with cancer. Cancer Treat Rev  35: 175-84, 2009
  490. Nakou ES, Filippatos TD, Kiortsis DN, Derdemezis CS, Tselepis AD, Mikhailidis DP, Elisaf MS. The effects of ezetimibe and orlistat , alone or in combination, on high-density lipoprotein (HDL) subclasses and HDL-associated enzyme activities in overweight and obese patients with hyperlipidaemia. Expert Opin Pharmacother  9: 3151-8, 2008
  491. Goto S, Bhatt DL, Rοther J, Alberts M, Hill MD, Ikeda Y, Uchiyama S, D’ Agostino R, Ohman EM, Liau CS, Hirsch AT, Mas JL, Wilson PW, Corbalan R, Aichner F, Steg PG; REACH Registry Investigators. Prevalence, clinical profile, and cardiovascular outcomes of atrial fifrillation patients with atherothrombosis.  Am Heart J  156: 855-63, 863e2, 2008
  492. Tsouli SG, Xydis V, Argyropoulou MI, Tselepis AD, Elisaf M, Kiortsis DN.Regression of Achilees tendon thickness after statin treatment in patients with familial hypercholesterolemia: An ultrasonographic study. Atherosclerosis  205: 151-5, 2009
  493. Elisaf M, Liberopoulos EN. Are the pleiotropic effects of drugs used for the prevention of cardiovascular disease clinically relevant? Curr Pharm Des  15: 463-6, 2009
  494. Tsimihodimos V, Liberopoulos E, Elisaf M. Pleiotropic effects of fenofibrate. Curr Pharm Des  15: 517-528, 2009
  495. Rizos C, Elisaf M, Mikhailidis D, Liberopoulos E. How safe is the use of thiazolidinediones in clinical practice? Expert Opin Drug Saf  8: 15-32, 2009
  496. Kostapanos MS, Liberopoulos EN, Elisaf MS. Statin pleitrophy against renal injury. J Cardiometab Syndr  4: E4-E9, 2009
  497. Kostapanos MS, Milionis HJ, Filippatos TD, Christogiannis LG, Bairaktari ET, Tselepis AD, Elisaf MS. Dose-dependent effect of rosuvastatin treatment on HDL-subfraction phenotype in patient swith primary hyperlipidemia. J Cardiovasc Pharmacol Ther  14: 5-13, 2009
  498. Panoulas VF, Douglas KM, Smith JP, Metsios GS, Elisaf MS, Nightingale P, Kitas GD. Galectin-2 (LGALS2) 3279C/T Polymorphism may be independently associated with diastolic blood pressure in aptients with rheumatoid arthritis. Clin Exp Hypertens  31: 93-104, 2009
  499. Milionis HJ, Giannopoulos S, Kosmidou M, Panoulas V, Manios E, Kyritsis AP, Elisaf MS, Vemmos K. Statin therapy after first stroke reduces 10-year stroke recurrence and improves survival. Neurology  72: 1816-22, 2009
  500. Filippatos TD, Randeva HS, Derdemezis CS, Elisaf MS, Mikhalidis DP. Visfatin/PBEF and atherosclerosis-related diseases. Curr Vasc Pharmacol 8: 12-28, 2010
  501. Tsimihodimos V, Kakaidi V, Elisaf M. Cola-induced hypokalemia: pathophysiological mechanisms and clinical implications. Int J Clin Pract  63: 900-2, 2009
  502. Chimonas T, Fanouraki I, Liberopoulos EN, Chimonas E, Elisaf M. Diverging trnds in cardiovascular morbidity and mortality in a low risk population.  Eur J Epidemiol  24: 415-23, 2009
  503. Apostolou F, Gazi IF, Kostoula A, Tellis CC, Tselepis AD, Elisaf M, Liberopoulos EN. Percistence of an atherogenic lipid profile after treatment of acute infection with Brucella.  J Lipid Res  50: 2532-9, 2009
  504. Tzovaras VT, Psychogios NG, Kostara CE, Bairaktari ET, Elisaf MS. Evaluation of the proximal tubular function in individuals with primary renal hypouricemia: an NMR –based metabonomic study.  NMR Biomed  22: 1072-83, 2009
  505. Tsimihodimos V, Gazi I, Filippatos T, Kostapanos M, Lagos K, Kostara C, Tellis CC, Elisaf M, Tselepis AD. Plasma triglycerides levels and body mass index values are the most important determinants of prebeeta-1 HDL concentrations in patients with various types of primary dyslipidemia. Atherosclerosis  208: 506-11, 2010
  506. Rizos SV, Elisaf MS, Liberopoulos EN. Are the pleiotropic effects of telmisartan clinically relevant? Curr Pharm Des  15: 2815-32, 2009
  507. Kostapanos MS, Milionis HJ, Agouridis AD, Rizos CV, Elisaf MS. Rosuvastatin treatment is associated with an increase in insulin resistance in hyperlipidemic patients with impaired fasting glucose. Int J Clin Pract 63: 1308-19, 2009
  508. Florentin M, Kostapanos MS, Nakou ES, Elisaf M, Liberopoulos EN. Efficacy and safety of ezetimibe plus orlistat or rimonabant in statin-intolerant nondiabetic overweight/obese patients with dyslipidemia. J Cardiovasc Pharmacol Ther  14: 274-82, 2009
  509. Liamis G, Milionis HJ, Elisaf M. A review of drug-induced hypocalcemia. J Bone Miner Metab  27: 635-42, 2009
  510. Elisaf M.S., Doumas M. Acid-base balance –electrolyte quiz-case 13. Archives of Hellenic Medicine  27: 133, 2010
  511. Elisaf M.S., Florentin M. Acid-base balance –electrolyte quiz-case 12. Archives of Hellenic Medicine  26: 713, 2009
  512. Elisaf M.S., Florentin M. Acid-base balance –electrolyte quiz-case 11. Archives of Hellenic Medicine  26: 567, 2009
  513. Elisaf M.S., Florentin M. Acid-base balance –electrolyte quiz-case 10. Archives of Hellenic Medicine  26: 423, 2009
  514. Elisaf M.S., Florentin M. Acid-base balance –electrolyte quiz-case 9. Archives of Hellenic Medicine  26: 277, 2009
  515. Elisaf M.S., Florentin M. Acid-base balance –electrolyte quiz-case 8. Archives of Hellenic Medicine  26: 130, 2009
  516. Florentin M, Elisaf MS, Mikhailidis DP, Liberopoulos EN. Drug combinations for dyslipidemia and obesity treatment in metabolic syndrome. Curr Pharm Des  15: 3446-62, 2009
  517. Florentin M, Liberopoulos EN, Tellis CC, Derdemezis CS, Elisaf M, Tselepis A. Effects of rimonabant as monotherapy and in combination with fenofibrate or ezetimibe, on plasma adipokine levels: a pilot study. Angiology 61(4):365-71, 2010
  518. Kostapanos MS, Milionis HJ, Elisaf MS. Does intensive cholesterol lowering increase the risk of diabetes? Int J Clin Pract  63: 1809, 2009
  519. Hermans MP, Castro Cabezas M, Strandberg T, Ferrieres J, Feely J, Elisaf M, Michel G, Sansoy V. Centralized Pan-European survey on the under –treatment of hypercholesterolemia (CEPHEUS): overall findings from eight countries. Curr Med Res Opin  26: 445-54, 2010
  520. Kostara C, Papathanasiou A, Cung MT, Elisaf M, Goudevenos I, Bairaktari E. Evaluation of established coronary heart disease on the basis of HDL and non-HDL NMR lipid profiling. J Proteome Res  9: 897-911, 2010
  521. Chimonas T, Athyros VG, Ganotakis E, Nikolaou V, Panagiotakos DB, Mikhailidis DP, Elisaf M. Assessing the treatment effect in metabolic syndrome without Perceptible diabeTes (ATTEMPT) Collaborative Group. Angiology  61: 49-57, 2009
  522. Miltiadous G, Tsimihodimos V, Elisaf M. Salicylate-induced Fanconi-like syndrome. Arch Med Scie 5;644-646, 2009
  523. Katsiki N, Tziomalos K, Chatzizisis Y, Elisaf M, Hatzitotlios AI. Effect of HMG-CoA reductase inhibitors on vascular cell apoptosis: Beneficial or detrimental? Atherosclerosis 211(1):9-14, 2010
  524. Korantzopoulos P, Tzimas P, Kalantzi K, Kostapanos M, Vemmos K, Goudevenos J, Elisaf M, Milionis H. Association between serum gamma-glutamyltransferace and acute ischemic nonembolic stroke in elderly patients. Arch Med Res  40: 582-9, 2009
  525. Kostapanos MS, Milionis HJ, Elisaf MS. Rosuvastatin –associated adverse effects and drug-drug interactions in the clinical setting of dyslipidemia. Am J Cardiovasc Drugs  10: 11-28, 2010
  526. Kalogirou M, Tsimohodimos V, Elisaf M. Pleiotropic effects of ezetimibe: Do they really exist? Eur J Pharmacol  633: 62-70, 2010
  527. Evangelou P, Tzotzas T, Christou G, Elisaf M, Kiortsis DN. Does the Presence of Metabolic Syndrome Influence Weight Loss in Obese and Overweight Women? Metab Syndr Relat Disord  8: 173-8, 2010
  528. Florentin M, Tselepis AD, Elisaf MS, Rizos CV, Mikhailidis DP, Liberopoulos EN. Effect of Non Statin Lipid Lowering and Anti-Obesity Drugs on LDL Subfractions in Patients with Mixed Dyslipidemia. Curr Vasc Pharmacol  8(6):820-30, 2010
  529. Moutzouri E, Florentin M, Elisaf MS, Mikhailidis DP, Liberopoulos EN. Aliskiren, a Direct Renin Inhibitor, in Clinical Practice: A new approach in the treatment of hypertension. Curr Vasc Pharmacol  2010
  530. Derdemezis CS, Filippatos TD, Mikhaildis DP, Elisaf MS. Effects of plant sterols and stanols beyond low-density lipoprotein cholesterol lowering. J Cardiovasc Pharmacol Ther 8(3):344-62, 2010
  531. Liamis G, Milionis HJ, Elisaf M. Medication–induced hypophosphatemia: a review. QJM  103(7):449-59, 2010
  532. Nakou ES, Filippatos TD, Agouridis AP, Kostara C, Bairaktari ET, Elisaf MS. The effects of ezetimibe and/or orlistat on triglyceride-rich lipoprotein metabolism in obese hypercholesterolemic patients. Lipids  45(5):445-50, 2010
  533. Liamis G, Milionis HJ, Elisaf M. Pharmacologically-induced metabolic acidosis: a review. Drug Saf  33: 371-91, 2010
  534. Rizos CV, Milionis HJ, Kostapanos MS, Florentin M, Kostara CE, Elisaf MS, Liberopoulos EN. Effects of rosuvastatin combined with olmesartan , irbesartan, or telmisartan on indices of glucose metabolism in Greek adults with impaired fasting glucose, hypertension, and mixed hyperlipidemia: a 24 week , randomized , open-label, prospective study. Clin Ther  32: 492-505, 2010
  535. Elisaf MS, Nikas N. Centralized Pan European survey on the undertreatment of hypercholesterolemia in patients using lipid lowering drugs-the CEPHEUS-Greece survey. Angiology  61: 465-74, 2010
  536. Kostapanos MS, Milionis HJ, Elisaf MS. Current role of statins in the treatment of essential hypertension. Expert Opin Pharmacother  11: 263-50, 2010
  537. Rizos EC, Agouridis AP, Elisaf MS. The effect of statin therapy on arterial stiffness by measuring pulse velocity: a systematic review. Curr Vasc Pharmacol  8: 638-44, 2010
  538. Kostapanos MS, Liamios GL, Milionis HJ, Elisaf MS. Do statins beneficailly or adversely affect glucose homeostasis? Curr Vasc Pharmacol  8: 612-3, 2010
  539. Kostapanos MS, Christogiannis LG, Bika E, Bairaktari ET, Goudevenos JA, Elisaf MS, Milionis HJ. Apoliprotein B-to –A1 Ratio as a predictor of acute nonembolic stroke in elderly subjects.  J Stroke Cerebrovasc Dis  19: 497-502, 2010
  540. Liberopoulos EN, Florentin M, Elisaf MS, Mikhailidis DP, Tsianos EP. Fenofibrate in primary biliary cirrhosis: a pilot study. Open Cardiovasc Med J  4: 120-6, 2010
  541. Rizos EC, Elisaf MS. Current topics on hypolipidaemic therapy and cardiovascular risk assessment. Curr Vasc Pharmacol  8: 587-8, 2010
  542. Apostolou F, Gazi IF, Lagos K, Tellis CC, Tselepis AD, liberopoulos EN, Elisaf M. Acute infection with Epstein-Barr virus is associated with atherogenic lipid changes. Atherosclerosis  212: 607-13, 2010
  543. Elisaf M, Kostapanos M. Acid-base balance –electrolyte quiz-case 18. Archives of Hellenic Medicine  27: 858, 2010
  544. Elisaf M, Kostapanos M. Acid-base balance-electrolyte quiz-case 17. Archives of Hellenic Medicine  27: 714, 2010
  545. Elisaf M, Filippatos T. Acid base balance-electrolyte quiz-case 16. Archives of Hellenic Medicine  27: 563, 2010
  546. Elisaf M, Filippatos T. Acid-base balance-electrolyte quiz-case 15. Archives of Hellenic Medicine  27: 276, 2010
  547. Elisaf M, Florentin M. Acid-base balance –electrolyte quiz-case 14. Archives of Hellenic Medicine  27: 133, 2010
  548. Moutzouri E, Elisaf M, Liberopoulos EN. Hypocholesterolemia. Curr Vasc Pharmacol  9(2):200-12, 2011
  549. Liberopoulos EN, Florentin M, Kei A, Mountzouri E, Agouridis A, Elisaf M. Comparison of hemoglobin A1c and fasting glucose criteria to diagnose diabetes among people with metabolic syndrome and fasting glucose above 100mg/dl (5.5mmol/L). J Clin Hypertens  12: 543-8, 2010
  550. Xita N, Milionis HJ, Galidi A, Lazaros L, Katsoulis K, Elisaf MS, Georgiou I, Tsatsoulis A. The (TAAAA)n Polymorphism of the SHBG Gene in men with metabolic syndrome. Exp Clin Endocrinol Diabetes 119(2):126-8, 2011
  551. Chimonas T, Karagiannis a, Athyros VG, Achimastos A, Elisaf M, Panagiotakos DB. Blood pressure levels constitute the most important determinant of the metabolic syndrome in a mediterranean population: A discrimination analysis. Metab Syndr Relat Disord 8(6):523-9, 2010
  552. Suarez C, Zeymer U, Limbourg T, Baumgartner I, Cacoub P, Poldermans D, Rother J, Bhatt DL, Steg PG; REACH Registry Investigators. Vasc Med  15: 259-65, 2010
  553. Moutzouri E, Kei A, Elisaf MS, Milionis HJ. Management of dyslipidemias with fibrates, alone and in combination with statins: role of delayed –release fenofibric acid. Vasc Health Risk Manag  6: 525-39, 2010
  554. Agouridis AP, Filippatos TD, Derdemezis Cs, Mikhailidis DP, Elisaf MS. Combination of fenofibrate with non-statin drug regimens. Curr Pharm Des 16: 3401-16, 2010
  555. Florentin M, Elisaf MS, Mikhailidis DP, Liberopoulos EN. Vitamin D and Metabolic Syndrome: Is there a link? Curr Pharm Des  16: 3417-34, 2010
  556. Tzamaloukas AH, Ing TS, Elisaf MS, Raj DS, Siamopoulos KC, Rohrscheib M, Murata GH. Abnormalities of serum potassium concentration in dialysis –associated hyperglycemia and their correction with insulin: review of published reports. Int Urol Nephrol  43(2):451-9, 2011
  557. Liberopoulos E.N., Florentin M., Elisaf M.S., Mikhailidis D.P., Tsianos E. Fenofibrate in primary biliary cirrhosis: a pilot study. Open Cardiovasc Med  4: 120-126, 2010
  558. Nakou E.S., Elisaf M.S., Liberopoulos E.N. High-sensitivity C-reactive protein: to measure or not to measure? Open Clin Chem J  3: 10-18, 2010
  559. Christogiannis L., Milionis H.J., Elisaf M. Lipoprotein (a) and stroke: An overview. Open Clin Chem J  3: 38-43, 2010
  560. Milionis H.J., Elisaf M.S. Emerging biomarkers for the optimal assessment of global cardiovascular risk: Where do we stand? Open Clin Chem J  3: 8-9, 2010
  561. Tzamaloukas AH, Ing TS, Elisaf MS, Raj DS, Siamopoulos KC, Rohrscheib M, Murata GH. Abnormalities of serum potassium concentration in dialysis –associated hyperglycemia and their correction with insulin: a unique clinical/physiologic exercise in internal potassium balance. Int Urol Nephrol  42: 1015-22, 2010
  562. Diakou M, Miltiadous G, Xenophontos S, Elisaf M. Characterization of low density lipoprotein receptor (LDLR) gene mutations in Albania. Arch Med Scie 6; 198-200, 2010
  563. Liamis G, Milionis HJ, Elisaf M. Endocrine disorders: causes of hyponatremia not to neglect.  Ann Med 43(3):179-87, 2011
  564. Kei AA, Florentin M, Mikhaildis DP, Elisaf MS, Liberopoulos EN. Antiplatelet drugs: what comes next? Clin Appl Thromb Hemost  17: 9-26, 2010
  565. Filippatos TD, Elisaf M. Combination drug treatment in patients with non-alcoholic fatty liver disease. World J Hepatol  2: 139-42, 2010
  566. Florentin M, Liberopoulos EN, Moutzouri E, Rizos CV, Tselepis AD, Elisaf MS. The effect of simvastatin alone versus simvastatin plus ezetimibe on the concentration of small dense low-density lipoprotein cholesterol in subjects with primary hypercholesterolemia.  Curr Med Res Opin  27: 685-92, 2011
  567. Kei A, Liberopoulos EN, Elisaf MS. What restricts the clinical use of nicotinic acid?  Curr Vasc Pharmacol  2011
  568. Florentin M, Liberopoulos EN, Kei A, Mikhailidis DP, Elisaf MS. Pleiotropic effects of nicotinic acid: beyond high density lipoprotein cholesterol elevation. Curr Vasc Pharmacol  2011
  569. Florentin M, Liberopoulos EN, Mikhailidis DP, Elisaf MS. Emerging options in the treatment of dyslipidemias: a bright future?  Expert Opin Emerg Drugs  16(2):247-70, 2011
  570. Agouridis AP, Tsimihodimos V, Filippatos TD, Tselepis AD, Elisaf MS. High doses of rosuvastatin are superior to low doses of rosuvastatin plus fenofibrate or n-3 fatty acids in mixed dyslipidemia.  Lipids 46(6):521-8, 2011
  571. Rizos CV, Liberopoulos EN, Tellis CC, Florentin M, Elisaf MS, Tselepis AD. Combining rosuvastatin with sartans of different peroxisome proliferator-activated receptor-γ activating capacity is not associated with different changes in low-density lipoprotein subfractions and plasma lipoprotein –associated phosholipase A2.  Metab Syndr Relat Disord 9(3):217-23, 2011
  572. Kostapanos MS, Spyrou AT, Tellis CC, Gazi IF, Tselepis AD, Elisaf M, Liberopoulos EN. Ezetimibe treatment lowers indicators of oxidative stress in hypercholesterolemic subjects with high oxidative stress.  Lipids 46: 341-8, 2011
  573. Tzovaras V, Tsimihodimos V, Kostara C, Mitrogianni Z, Elisaf M. Aminoglycoside –induced nephrotoxicity studied by proton magnetic resonance spectroscopy of urine.  Nephrol Dial Transplant  2011
  574. Tziallas D, Kastanioti C, Kostapanos MS, Skapinakis P, Elisaf MS, Mavreas V. The impact of the metabolic syndrome on health-related quality of life: a cross –sectional study in Greece.  Eur J Cardiovasc Nurs  2011
  575. Christodoulou DK, Milionis HJ, Pappa P, Katsanos KH, Sigounas D, Florentin M, Elisaf M, Tsianos EV. Association of Helicobacter pylori infection with cardiovascular disease-Is it just a myth?  Eur J Intern Med  22: 191-4, 2011
  576. Agouridis AP, Filippatos TD, Tsimihodimos V, Elisaf MS. Combinations of ezetimibe with nonstatin drug regimens affecting lipid metabolism.  Expert Rev Cardiovasc Ther 9: 355-66, 2011
  577. Tsimihodimos V, Elisaf M. Lipoprotein glomerulopathy. Curr Opin Lipidol  22(4):262-9, 2011
  578. Tziallas D, Kostapanos MS, Skapinakis P, Milionis HJ, Athanasiou T, Elisaf MS, Mavreas V. The association between Type D personality and the metabolic syndrome: a cross-sectional study in a University-based outpatient lipid clinic. BMC Res Notes  4: 105, 2011
  579. Athyros VG, Ganotakis E, Kolovou GD, Nicolaou V, Achimastos A, Bilianou E, Alexandrides T, Karagiannis A, Liberopoulos EN, Tziomalos K, Petridis D, Kakafika A, Elisaf MS, Mikhailidis DP, for the Assessing the Treat in Metabolic Syndrome Without Perceptible Diabetes (ATTEMPT) Collaborative. Assessing the treatment effect in metabolic syndrome without perceptible diabetes (ATTEMPT): a prospective- randomized study in middle aged men and women. Curr Vasc Pharmacol  2011
  580. Mikhailidis DP, Elisaf MS, Rizzo M, Berneis K, Griffin B, Zambon A, Athyros V, de Graaf J, Marz W, Parhofer Tomkin GH, Tselepis AD, Wierzbicki AS, Winkler K, Florentin M, Liberopoulos EN. European Panel on low density lipoprotein (LDL) subclasses: A statement on the Pathophysiology, a significance of LDL subclasses.  Curr Vasc Pharmacol  2011
  581. Mikhailidis DP, Elisaf MS, Rizzo M, Berneis K, Griffin B, Zambon A, Athyros V, de Graaf J, Marz W, Parhofer Tomkin GH, Tselepis AD, Wierzbicki AS, Winkler K, Florentin M, Liberopoulos EN. European Panel on low density lipoprotein (LDL) subclasses: A statement on the Pathophysiology, a significance of LDL subclasses. Executive Summary.  Curr Vasc Pharmacol  2011
  582. Christou GA, Tellis CC, Elisaf MS, Tselepis AD, Kiortsis DN. The changes in plasma retinol-binding protein 4 levels are associated with those of the apolipoprotein B-containing lipoproteins during dietary and drug treatment.  Angiology  2011
  583. Moutzouri E, Ntaios G, Elisaf M, Milionis HJ. Pharmaceutical modulation of the renin angiotensin aldosterone system for stroke prevention: a review of experimental and clinical evidence.  CNS Spectr 2010
  584. Tsimihodimos V, Mitrogianni Z, Elisaf M. Dyslipidemia associated with chronic kidney disease.  Open Cardiovasc Med 2011;5: 41-8
  585. Elisaf M, Tsimihodimos V. Edtorial: Secondary dyslipidemias.  Open Cardiovasc Med J 2011;5: 22-3
  586. Rizos CV, Elisaf MS, Liberopoulos EN. Effects of thyroid dysfunction on lipid profile.  Open Cardiovasc Med J5: 76-84, 2011
  587. Liberopoulos E, Vlasserou F, Mitrogianni Z, Papageorgantas I, Elisaf M. Prevalence and risk distribution of residula dyslipidemia in statin-treated patients in Greece.  Angiology 2011
  588. Gazi IF, Apostolou FA, Liberopoulos EN, Filippatos TD, Tellis CC, Elisaf MS, Tselepis AD. Leptospirosis is associated with markedly increased triglycerides and small dense Low –Density Lipoprotein and decreased High-Density lipoprotein.  Lipids 2011
  589. Agouridis AP, Tsimihodimos V, Filippatos TD, Dimitriou AA, Tellis CC, Elisaf MS, Mikhailidis DP, Tselepis AD. The effects of rosuvastatin alone or in combination with fenofibrate or omega 3 fatty acids on inflammation and oxidative stress in patients with mixed dyslipidemia.  Expert Opin Pharmacother  2011
  590. Miltiadous G, Elisaf M. Native valve endocarditis due to Micrococcus luteus: a case report and review of the literature.  J Med Case Reports  5: 251, 2011
  591. Katsiki N, Elisaf M. Multifactorial treatment for improvement of renal function and cardiovascular risk: an ATTEMPT for patients with metabolic syndrome and chronic kidney disease. Curr Med Res Opin. 2011
  592. Filippatos TD, Elisaf MS. Fenofibrate plus simvastatin (fixed-dose combination) for the treatment of dyslipidaemia. Expert Opin Pharmacother  2011
  593. Kei A, Florentin M, Elisaf M, Liberopoulos E. Anticoagulant drugs: what is new? Int Angiol  30(4):299-320, 2011
  594. Kei A, Elisaf M, Moutzouri E, Tsiara S, Liberopoulos E. Add-on-Statin Extended Release Nicotinic Acid/Laropiprant but Not the Switch to High-Dose Rosuvastatin Lowers Blood Pressure: An Open-Label Randomized Study. Int J Hypertens 2011:830434, 2011
  595. Makariou S, Liberopoulos EN, Elisaf M, Challa A. Novel roles of vitamin D in disease: What is new in 2011? Eur J Intern Med. 22(4):355-62, 2011
  596. Kalaitzidis RG, Elisaf MS. The Role of Statins in Chronic Kidney Disease. Am J Nephrol. 34(3):195-202, 2011
  597. Miltiadous G, Elisaf M. Acid-base balance-electrolyte quiz- Case 20. Arch Hell Med 28: 428; 2011
  598. Tziallas D, Kostapanos MS, Skapinakis P, Milionis HJ, Athanasiou TS, Elisaf M, Mavreas V. The association between type D personality and the metabolic syndrome: A cross-sectional study in a university-based outpatient lipid clinic. BMC Research Notes 4: 105; 2011
  599. Polikandrioti M, Goudevenos I, Michalis L, Nikolaou V, Dilanas C, Olympios C, Votteas V, Elisaf M. Validation and reliability analysis of the questionnaire “Needs of hospitalized patients with coronary artery disease”. Health Sci J 5: 137-148; 2011
  600. Tsuzaki K, Kotani K, Sano Y, Fujiwara S, Gazi IF, Elisaf M, Sakane N. The relationship between adiponectin, an adiponectin gene polymorphism, and high-density lipoprotein particle size: from the Mima study. Metabolism, 2011
  601. Liamis G, Milionis HJ, Elisaf M. Hyponatremia in patients with infectious diseases. J Infect, 2011
  602. Kostapanos MS, Elisaf MS. Jupiter and satellites: Clinical implications of the JUPITER study and its secondary analyses. World J Cardiol 3:207-14;2011
  603. Diakou M, Miltiadous G, Xenopoulos SL, Manoli P, Cariolou MA, Eisaf M. Spectrum of LDLR gene mutations, including a novel mutation causing familial hypercholesterolaemia, in North-western Greece. Eur J Intern Med 22:e55-9; 2011
  604. Milionis HJ, Gerotziafas G, Kostapanos MS, Vemmou A, Zis P, Spengos K, Elisaf M, Vemmos KN. Clopidogrel vs. Aspirin Treatment on Admission Improves 5-Year Survival After a First-ever Acute Ischemic Stroke. Data from the Athens Stroke Outcome Project. Arch Med Res 2011
  605. Nobels F, Debacker N, Brotons C, Elisaf M, Hermans MP, Michel G, Muls E; the OPTIMISE(Optimal Type 2 diabetes Management Including benchmarking and Standard treatment) International Steering Committee. Study rationale and design of OPTIMISE, a randomized controlled trial on the effect of benchmarking on quality of care in type 2 diabetes mellitus. Cardiovasc Diabetol 10:82; 2011
  606. Derdemezis CS, Kiortsis DN, Tsimihodimos V, Petraki MP, Vezyraki P, Elisaf MS, Tselepis AD. Effect of Plant Polyphenols on Adipokine Secretion from Human SGBS Adipocytes. Biochem Res Int 2011:285618;2011
  607. Filippatos TD, Tsimihodimos V, Derdemezis CS, Gazi IF, Saougos V, Mikhailidis DP, Tselepis AD, Elisaf MS. Increased plasma visfatin concentration is amarker of an atherogenic metabolic profile. Nutr Metab Cardiovasc Dis 2011
  608. Moutzouri E, Liberopoulos E, Mikhailidis DP, Kostapanos MS, Kei AA, Milionis H, Elisaf M. Comparison of the effects of simvastatin vs. rosuvastatin vs. simvastatin/exetimibe on parameters of insulin resistance. Int J Clin Pract 65:1141-8;2011
  609. Liberopoulos EN, Kei AA, Elisaf MS.Lysis syndrome during therapy of visceral leishmaniasis. Inflection 2011
  610. Athyros VG, Elisaf MS, Alexandrides T, Achimastos A, Ganotakis E, Bilianou E, Karagiannis A, Liberopoulos EN, Tziomalos K, Mikhailidis DP. Long-Term Impact of Multifactorial Treatment on New-Onset Diabetes and Related Cardiovascular Events in Metabolic Syndrome: A Post Hoc ATTEMPT Analysis. Angiology 2011
  611. Moutzouri E, Tsimihodimos V, Rizos E, Elisaf M. Prediabetes: To treat or not to treat? Eur J Pharmacol 672: 9-19; 2011
  612. Filippatos TD, Elisaf MS. Role of ezetimibe in non-alchoholic fatty liver disease. World J Hepatol 3: 265-7; 2011
  613. Christogiannis LG, Kostapanos MS, Tellis CC, Milionis HJ, Tselepis AD, Elisaf MS. Distinct effects of fixed combinations of valsartan with either amlodipine or hydrochlorothiazide on lipoprotein subfraction profile in patients with hypertension.J Hum Hypertens 2011
  614. Punthakee Z, Bosch J, Dagenais G, Diaz R, Holman R, Probstfield JL, Ramachandran A, Riddle MC, Rydén LE, Zinman B, Afzal R, Yusuf S, Gerstein HC; TIDE Trial Investigators. Design, history and results of the Thiazolidinedione Intervention with Vitamine D Evaluation (TIDE) randomized controlled trial. Diabetologia 55:36-45; 2012
  615. Elisaf MS, Rizos EC. Editorial: current topics on the epidemiology, pathogenesis, and treatment of diabetes mellitus and its complications. Curr Vasc Pharmacol 10:138-9; 2012
  616. Rizos EC, Agouridis AP, Elisaf MS.Aliskerin in patients with diabetes: a systematic review. Curr Vasc Pharmacol 10:140-6; 2012
  617. Kostapanos MS, Katsiki N, Elisaf MS, Mikhailidis DP. Editorial: Reducing Cardiovascular risk: Is Low-Density Lipoprotein-Cholesterol (LDL-C) Lowering Enough? Curr Vasc Pharmacol 10:173-7; 2012
  618. Moutzouri E, Liberopoulos EN, Elisaf MS. Life-threatening hypophosphataemia in a cirrhotic patient with jaundice. Arch Med Sci 7:736-9; 2011
  619. Athyros VG, Giouleme O, Ganotakis ES, Elisaf M, Tziomalos K, Vassiliadis T, Liberopoulos EN, Theocharidou E, Karagiannis A, Mikhailidis DP. Safety and impact on cardiovascular events of long-term multifactorial treatment in patients with metabolic syndrome and abnormal liver function tests: a post hoc analysis of the randomised ATTEMPT study. Arch Med Sci 7:796-805; 2011
  620. Kei AA, Filippatos TD, Tsimihodimos V, Elisaf MS. A review of the role of apolipoprotein C-II in lipoprotein metabolism and cardiovascular disease. Metabolism; 2012;61(7):906-21
  621. Florentin M, Elisaf MS. Simvastatin interactions with other drugs. Expert Opin Drug Saf 2012;11(3): 439-44
  622. Makariou SE, Liberopoulos EN, Agouridis AP, Challa A, Elisaf M. Effect of Rosuvastatin monotherapy and combination with fenofibrate or omega-3 fatty acids on serum vitamin D-levels. J Cardiovasc Pharmacol Ther 2012;
  623. Liberopoulos E, Kei A, Apostolou F, Elisaf M. Autoimmune manifestations in patients with visceral leishmaniasis. J Microbiol Immunol Infect 2012
  624. Kostapanos MS, Elisaf MS, Mikhailidis DP. Effect of Atorvastatin monotherapy and low-dose Atorvastatin/Ezetimibe combination on fasting and postprandial triglycerides in combined hyperlipidemia. J Cardiovasc Pharmacol Ther 2012
  625. Moutzouri E, Liberopoulos EN, Florentin M, Liamis G, Elisaf MS. Effects of statin monotherapy versus statin plus Ezetimibe combination on serum uric acid levels. J Cardiovasc Pharmacol Ther 2012
  626. Gaitanis G, Alexis I, Pelidou SH, Gazi IF, Kyritsis AP, Elisaf MS, Bassukas ID. High-dose intravevenous immunoglobulin in the treatment of adult patients with bullous pemphigoid. Eur J Dermatol 2012;22:363-9
  627. Kei A, Elisaf MS. Nicotinic acid: clinical considerations. Expert Opin Drug Saf 2012; 11(4):551-64
  628. Hermans MP, Brotons C, Elisaf M, Michel G, Muls E, Nobels F. Optimal type 2 diabetes mellitus management: the randomized controlled OPTIMISE benchmarking study: baseline results from six European countries. Eur J Prev Cardiol 2012
  629. Rizos Ec, Ntzani EE, Papanas N, Tsimihodimos V, Mitrogianni Z, Maltezos E, Elisaf MS. Combination therapies of DPP4 inhibitors and GLP1 analogues with insulin in type 2 diabetic patients: A systematic review. Curr Vasc Pharmacol 2012
  630. Christou GA, Tellis KC, Elisaf MC, Tselepis AD, Kiortsis DN. High density lipoprotein is positively correlated with the changes in circulating total adiponectin and high molecular weight adiponectin during dietary and fenofibrate treatment. Hormones 2012;11(2):178-88
  631. Makariou S, Liberopoulos E, Florentin M, Lagos K, Gazi I, Challa A, Elisaf M. The relationship of vitamin D with non-traditional risk factors for cardiovascular disease in subjects with metabolic syndrome. Arch Med Sci 2012;8(3):437-43
  632. Kostapanos MS, Elisaf MS, Mikhailidis DP. Targeting cardiovascular risk: the impact of age, gender and compliance to treatment. Curr Med Res Opin 2012;28(9): 1415-9
  633. Agouridis AP, Kostapanos MS, Tsimihodimos V, Kostara C, Mikhailidis DP, Bairaktari ET, Tselepis AD, Elisaf MS. Effect of rosuvastatin monotherapy or in combination with fenofibrate or ω-3 fatty acids onlipoprotein subfraction profile in patients with mixed dyslipidaemia and metabolic syndrome. Int J Clin Pract 2012;66(9): 843-53
  634. Rizos EC, Ntzani EE, Bika E, Kostapanos MS, Elisaf MS. Associationbetween omega-3 fatty acid supplementation and risk of major cardiovascular disease events: a systematic review and meta-analysis. JAMA 2012;308(10):1024-33
  635. Moutzouri E, Tellis CC, Rousouli K, Liberopoulos EN, Milionis HJ, Elisaf MS, Tselepis AD. Effect of simvastatin or its combination with ezetimibe on Toll-like receptor expression and lipopolysaccharide –induced cytokine production in monocytes of hypercholesterolemic patients. Atherosclerosis 2012

References:-

  • Mitsios JV, Papathanasiou AI, Rodis FI, Elisaf M, Goudevenos JA, Tselepis AD. Atorvastatin does not affect the antiplatelet potency of clopidogrel when it is administered concomitantly for 5 weeks in patients with acute coronary syndromes. Circulation 2004;109: 1335-8.
  • Rizos EC, Ntzani EE, Bika E, Kostapanos MS, Elisaf M. Association between omega-3 fatty acid supplementation and risk of major cardiovascular disease events: a systematic review and meta-analysis. JAMA 2012;308: 1024-33.
  • Stability Investigators, Elisaf M. Darapladib for preventing ischemic events in stable coronary heart disease. N Engl J Med 2014;370: 1702-11.
  • Tsimihodimos V, Karabina SA, Tambaki AP, Bairaktari E, Miltiadous G, Goudevenos JA, Cariolou MA, Chapman MJ, Tselepis AD, Elisaf M. Altered distribution of platelet –activating factor-acetylhydrolase activity between LDLand HDL as a function of the severity of hypercholesterolemia. J Lipid Res 2002;43: 256-63.
  • Saougos VG, Tambaki AP,Kalogirou M, Kostapanos M, Gazi IF, Wolfert RL, Elisaf M, Tselepis AD. Differential effect of hypolipidemic drugs on lipoprotein –associated phospholipase A2. Arterioscler Thromb Vasc Biol 2007;10: 2236-43.

 

Moses S. Elisaf

Professor

 

  • : +302651-0-07509
  • : +302651-0-07016
  • DEPARTMENTDirector of the second department of internal medicine of the university hospital of ioannina
    Director of division of nephrology of the university hospital of ioannina
    Head of the lipids, atherosclerosis obesity and diabetes clinic of the university hospital of ioannina Medical school,
    University of ioannina
  • COUNTRY Greece